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SOMMARIO 
Il microambiente tumorale, ossia l’insieme di cellule e componenti extracellulari 
che si sviluppano attorno ad un tumore solido, non solo partecipa attivamente alla 
progressione del tumore stesso, ma anche contribuisce allo sviluppo della 
chemioresistenza e alla comparsa di metastasi.  A causa della struttura anomala 
dei vasi sanguigni e della rapida proliferazione delle cellule tumorali, l’ambiente 
tumorale è in alcune parti caratterizzato da zone di parziale o totale ipossia. 
Sebbene gran parte delle cellule tumorali non sopravviva in queste condizioni 
ipossiche, una parte di esse si adatta, entrando in uno stato di dormienza, una 
particolare fase della progressione del tumore, in cui le cellule presentano un 
basso flusso metabolico e sono bloccate nella fase G0/G1 del ciclo cellulare. 
Queste cellule possono restare quiescenti per molto tempo senza dare sintomi 
clinici, sfuggire alle terapie e in condizioni ambientali appropriate ricominciare a 
proliferare dando origine a metastasi.  
Sebbene molti dati sperimentali e clinici individuino nella dormienza uno dei 
principali responsabili della formazione di metastasi e del fallimento di alcune 
chemioterapie, tale fenomeno rimane un processo non ancora completamente 
chiarito in quanto sono presenti pochi modelli cellulari in vitro che permettono di 
definire le risposte biologiche delle cellule dormienti. 
In questo lavoro, esponendo la linea cellulare umana di tumore al seno MDA-MB-
231 ad almeno 3 cicli di ipossia (1% O2) e successiva riossigenazione, abbiamo 
selezionato una sub-popolazione di cellule resistenti all’ipossia. Tali cellule, 
chiamate chMDA-MB-231, coltivate in ipossia per lungo tempo sopravvivono, 
entrando in uno stato di dormienza.   
La trasformazione delle cellule MDA-MB-231 in chMDA-MB-231 è legato alla 
diminuzione del rapporto p-ERK/p-p38, uno dei principali switch molecolari della 
dormienza in un microambiente avverso descritti in letteratura. Questo stato di 
dormienza è reversibile poiché, una volta rimesse le cellule in normossia, la 
proliferazione riprende in 2 settimane.  
Inoltre, i risultati ottenuti dimostrano che lo stress indotto da diversi cicli di 
ipossia e riossigenazione ha selezionato cellule con un fenotipo staminale CD24-
/CD44+/ESA+ e caratterizzate dalla capacità di formare sferoidi. 
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Infine, le cellule chMDA-MB-231 sopravvivono in queste condizioni di 
dormienza attivando il processo autofagico in quanto presentano alti livelli di 
autofagolisosomi e della proteina LC3-II. 
In conclusione, il modello presentato rappresenta un valido approccio 
sperimentale per selezionare cellule dormienti caratterizzate da marcatori di 
staminalità tumorale utile per lo sviluppo di nuovi agenti chemioterapici che 
possano colpire tali cellule, impedendo loro di formare metastasi, o renderle 
maggiormente sensibili ai chemioterapici. 
 
 
ABSTRACT 
The tumor microenvironment (TME) is recognized as a key factor in multiple 
stages of disease progression, local resistance, immune-escaping and metastasis. 
TME is the product of developing crosstalk between different cells types and 
components, which provide an essential communication network through the 
secretion of growth factors and chemokines, and induce oncogenic signals 
enhancing cancer-cell proliferation and invasion.  
The rapid proliferation of tumor cells and the aberrant structure of the blood 
vessels within tumors result in a marked heterogeneity in the perfusion of the 
tumor tissue with regions of low oxygen or hypoxia. Although most of the tumor 
cells die in these hypoxic conditions, a part of them can adapt and survive for 
many days or months in a dormant state. Dormant tumor cells are characterized by 
cell cycle arrest in G0/G1 phase as well as low metabolism and, are refractive to 
common chemotherapy giving rise to metastasis. Despite these features, the cells 
retain their ability to proliferate when conditions improve.  
Exposing human breast cancer cell line exposure MDA-MB-231 to at least three 
cycles of 1% O2 hypoxia and reoxygenation, we select a subpopulation of hypoxia 
resistant cells. These cells, designed as chMDA-MB-231, stably survive under 1% 
O2 hypoxia condition by entering in dormant state. The reprogramming of cells 
into tumor dormancy results from the low p-ERK/p-p38 ratio that is described as 
the molecular switch of tumor dormancy in restrictive environment. This dormant 
state is reversible since once replaced in normoxia the cells recover the 
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proliferation rate in 2 weeks. Moreover, the data in this thesis demonstrate that 
cycling hypoxic/reoxygenation stress selects dormant MDA-MB-231 cells that 
present the cancer stem-like phenotype characterized by CD24-/CD44+/ESA+ 
expression and spheroid forming capacity.  
Different reports recognize autophagy as a mechanism activated by 
microenvironment stresses that may contribute to survival of cells in tumor 
dormancy. Interestingly, we found that chMDA-MB-231 cells have a high level of 
autophagy, as measured by the detection of autophagolysome and LC3-II 
expression, suggesting that autophagy may be the survival mechanism of dormant 
chMDA-MB-231 cells.  
We believe that the proposed experimental approach to select dormant breast 
cancer cells could provide a rationale for the development of novel agents to 
target dormant tumor cells population.  
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1. INTRODUCTION 
1.1 Tumor microenvironment  
For many years, cancer has been considered a complex disease driven by genetic 
mutations and genomic instability. It is now clear that cancers are not just masses 
of malignant cells but also intricate organs, to which cells are recruited and 
interaction between malignant and non-transformed cells contributes to the 
development and progression of cancer itself.    
Tumor microenvironment (TME) is comprised of a complex network of 
components that are not mere bystanders, but regulate tumor initiation, malignant 
progression and metastasis and has profound effects on therapeutic efficacy (1). 
These elements can be widely classified into three main groups: (i) cells of 
haematopoietic origin, (ii) cells of mesenchymal origin and (iii) non-cellular 
components (Figure 1) (2). First, cells of haematopoietic origin arise in the bone 
marrow and can be subdivided into cells of lymphoid lineage consisting of T cells, 
B cells, natural killer cells, and those of the myeloid lineage, which include 
macrophages, neutrophils and myeloid-derived suppressor cells. The different 
subsets of cells have either positive or negative effects on the outcome of the 
tumor. Importantly, interactions between cell types within the stroma can also 
have a major role in tumor progression, as has been shown, for example for CD4+ 
T cells and macrophages (3). 
Then, cells of mesenchymal origin derive from the mesenchyme and include 
fibroblasts, myofibroblasts, mesenchymal stem cells, adipocytes and endothelial 
cells. Myofibroblast and mesenchymal stem cells directly support cancer stem 
cells (CSCs) by creating a favorable niche and facilitating tumor progression, 
while endothelial cells constitute the walls of blood vessels and have a major role 
in vascular functionally and angiogenesis. So far, adipocytes were thought only as 
energy storage houses; however, recent studies have revealed the importance of 
factors secreted by adipocytes in tumor progression (1). 
Finally, the extracellular matrix, the major non-cellular component of the TME, is 
involved in the formation of a stem cell niche. Although it acts to maintain tissue 
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architecture and prevent cancer cells formation, an abnormal ECM has been 
shown to promote tumor growth and angiogenesis (4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Components of tumor microenvironment. In TME there are cells of hematopoietic 
origin (T-cells, B-cells and NK-cells), cells of myeloid lineage (macrophages, neutrophils and 
myeloid-derived suppressor cells), cells of mesenchymal origin (fibroblasts, myofibroblasts, 
mesenchymal stem cells –MSCs-, adipocytes, endothelial cells and extracellular matrix (ECM). 
Image taken from: “What constitutes the tumor microenvironment: Tackling the cancer stem cells 
- what challenges do they pose? Pattabiraman et al., Nat Rev Drug Discov, 2014”. 
 
Many hallmarks of cancer are related to TME, including the ability to induce 
proliferation and inhibit apoptosis, to reprogram metabolism, to increase factors 
that support cancer invasion and metastasis and to promote angiogenesis and 
avoid hypoxia.  
Because the rapid proliferation of the cells requires an accelerated production of 
basic cellular building blocks, differences in cellular metabolic programs occur 
within the cells of TME and some proteins, such as HIF-1α, P13K, AKT, p53, 
PTEN, known as crucial components in the metabolic pathways, can be 
differently regulated in cancer cells (6). Although recent studies have revealed the 
importance of fatty acids and proteins as fuel sources for cancer cells, aerobic 
glycolysis (Warburg effect) remains the major fuel source for tumor cells (7). It is 
well described that cancer cells can metabolize 10-fold more glucose to produce 
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lactate than normal tissues. Despite enhanced glycolysis, most cancer cells also 
maintain mitochondrial respiration to produce a significant fraction of ATP. The 
metabolic switch of cancer cells toward a more glycolytic phenotype increases the 
concentration of protons [H+], causing the acidification of cytoplasm. To 
overcome low intracellular pH (pHi), cancer cells employ a large redundancy of 
mechanisms, such as the activation of plasma membrane proton pump ATPase 
(V-ATPase), carbonic anhydrases (CAIXs) and Na+/H+ exchangers or anion 
exchangers that determine a slow increase of pHi. In response to H+ efflux, the pH 
of tumor extracellular space (pHe) becomes acidic, forming a reversed pH 
gradient. The acidosis of TME promotes cancer progression and induces 
migration and invasion (8). 
Moreover, TME is characterized by disorganized blood vessels that are immature, 
tortuous and hyperpermeable. The tumor vasculature is typically a complex 
labyrinth of vessels in which arterioles, capillaries, and venules are not clearly 
identifiable. Furthermore, tumor vessels are more permeable than normal ones 
because they are poorly invested with smooth muscle cells, and have a 
discontinuous endothelial cell lining with an abnormal basement membrane. 
Increased vessel permeability results in aberrant osmotic forces, leading to 
accumulation of vascular contents and elevated interstitial fluid pressure. As 
result, the irregular vasculature system leads to impaired blood flow of tumor, 
where vessels cannot supply nutrient to cells and remove waste products. In 
addition, the aberrant geometry of vessels causes an inadequate oxygen supply to 
tumor cells with micro-regional hypoxia. These particular characteristics of tumor 
vasculature lead to adverse micro-environmental conditions that obstruct 
traditional therapeutic anti-cancer strategies (9,10).  
Overall, the manipulation of TME could be used as a valid approach to formulate 
new therapeutical cancer treatment and identifying the most important molecular 
players in TME represents the first step toward this goal. 
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1.1.1 Hypoxia in tumor microenvironment 
O2 is an important factor in cells metabolism and the maintenance of O2 
homeostasis is essential for the survival of the cells. Indeed, O2 is the final electon 
acceptor during mitochondrial ATP production and other intracellular reactions.  
As described above, most of solid tumors are characterized by regions of hypoxia, 
which result from structural abnormalities of vasculature network, rapid growth of 
tumor cells and high interstitial pressure. In this microenvironment cells undergo 
genetic and adaptive changes that allow them to survive and even proliferate. 
Tumor tissues are characterized by 1-2% O2 levels or below; these concentrations 
depend on the initial oxygenation of the tissue, the size and the stage of the tumor 
as well as on the methods of measurements and in which part of the measurement 
is performed. 
The two most frequently described and investigated subtypes of tumor hypoxia 
are acute and chronic. These two subtypes can lead to completely different 
hypoxia-related responses within the tumor, which could have a direct effect on 
tumor development and response to treatment. In order to accurately assess the 
specific biological consequences, it is important to understand which time frames 
best define acute and chronic hypoxia. The discrepancy and lack of clear 
description about the time frames and the biological consequences of acute and 
chronic hypoxia are often considered a great problem in oncology (11,12). 
Generally, it is accepted that acute hypoxia is an abrupt and brief exposure to 
hypoxia, which occurs when vessel occlusion lasts for several minutes until hours. 
It is reversible and often leads to following oxygen fluctuations called cycling 
hypoxia (13,14). Different in vitro models of acute hypoxia are set up by exposing 
cells to continuous hypoxia between few minutes to 72 hours. Short-term hypoxia 
allows cells to survive by activating different mechanisms such as autophagy that 
is achieved by decreasing oxidative metabolism. Furthermore, it has been 
described that high level of reactive oxygen species (ROS) induced by acute or 
cycling hypoxia may contribute to tumor cells survival (13,15). Conversely, 
enduring changes in blood flow and low oxygen availability, which are especially 
pronounced in larger tumors, result in chronic hypoxia and contribute to long-term 
cellular changes. In experimental setting, chronic conditions are achieved 
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incubating the cells in hypoxia between few hours and as long as several weeks. 
Longer exposure to hypoxia is associated with high frequency of DNA breaks, 
accumulation of DNA replication errors since hypoxia hampers DNA repair 
systems leading to genetic instability and mutagenesis. Moreover, chronic 
hypoxia induces metabolic switch from oxidative phosphorylation to anaerobic 
glycolysis that leads to continuous lactate production from pyruvate resulting in 
acidosis (16).  Even if both acute and chronic hypoxia can increase resistance to 
therapy, chronic hypoxia is associated with more aggressive tumor phenotype 
through the development of micro-niches of quiescent cells and induction of 
spontaneous metastasis (11,17,18). In any case, cycling hypoxia/reoxygenation 
represents the oxygenation state that better reflects in vivo situation. The 
biological responses activated by reoxygenation can instigate continuous adaptive 
mechanisms that contribute to increase the aggressiveness of the cancer cells. 
Thus, the chemoresistance, the radio-resistance and the ability to proliferate or 
metastasize are extensively enhanced during hypoxia/reoxygenation cycles.  
Although different hypoxic stimuli within tumors makes it difficult to generalize 
the real effects on tumor biology, and metabolism, it is now well known that  the 
biology of hypoxic cancer cells is the product of the interplay between the 
prevailing oxygen tension, hypoxia-induced signaling, and cellular damage by 
ROS (13). 
1.1.2 Signaling pathways in hypoxic tumor microenvironment: 
hypoxia inducible factors  
Hypoxia inducible factors (HIFs) are heterodimeric transcription factors 
consisting in a stable and constitutively expressed β-subunit (HIF-1β) and an 
oxygen sensitive α-subunit (HIF-1α). To date, three isoforms of HIF-α subunit 
(HIF-1α, HIF-2α and HIF-3α) have been described, from which HIF-1α and HIF-
2α are the best characterized. While HIF1α is expressed ubiquitously, HIF2α is 
expressed in more restricted number of cell types such as hepatocytes and 
endothelial cells. 
HIF activation is a multi-step process involving HIF-α stabilization, nuclear 
translocation, heterodimerization with HIF-1β and transcriptional activation of 
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genes that function in angiogenesis, tumor vascularization and chemoresistance. 
The key regulation of HIF-1 signaling is orchestrated by two types of oxygen-
sensor proteins: prolyl hydroxylase (PHDs) and asparaginyl hydroxylase (FIH), 
known as factors inhibiting HIF-1α through hydroxylation under normoxic 
condition. Specifically, PHDs hydroxylate two conserved prolyl residues in HIF-
1α allowing a rapid interaction with the von Hippel-Lindau tumor-suppression 
protein (VHL), a component of E3 ubiquitin ligase complex. Subsequently, HIF-
1α becomes marked with polyubiquitin chains that drive them to destruction by 
the proteasome system. 
Another oxygen-dependent major mechanism for negative regulation of HIF-1α 
pathway does not involved VHL protein. In this case, FIHs hydroxylate an 
asparagine residue in the carboxy-terminal transcriptional activation domain (C-
TAD) of HIF-α and block the cooperative interaction with the co-activator 
CBP/p300 impairing HIF-1α gene transcription (19). Thus, PHDs and FIHs 
ensure full repression of the HIF pathway under normoxia condition by 
controlling both the degradation and inactivation of HIF-1α subunit.  
On the other hand, when the oxygen level drops, the hydroxylases lose their 
activity and HIF-1α is stabilized ,  translocates to the nucleus where dimerize with 
the constitutively expressed HIF-1β subunit. HIF complex binds to DNA in the 
hypoxia-response elements (HRE) region and promotes transcription of genes  
involved in angiogenesis, metabolic adaptation, survival, apoptosis and cells 
migration (20).  
Figure 2 is a schematic representation of HIF-1α signaling pathway under 
normoxia and hypoxia.  
Introduction 
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Figure 2. HIF-1α oxygen-dependent regulation. HIF-1α protein is oxygen-sensitive and its 
stability dependes on O2 level. In normoxic conditions, PHD enzymes hydroxylate proline 402 and 
564 in HIF-1α allowing a rapid poly-ubiquitylation and subsequently proteasome degradation. 
Furthermore, FIH-1 hydroxylates asparagine 803 in HIF-1α impairing its DNA binding. Under 
hypoxic conditions, the rate of asparagine and proline hydroxylation decreases and HIF-1a that is 
not prolyl-hydroxylated is not degradated. HIF-1α dimerizes with the β-subunit and translocates to 
the nucleus. P402 and P564, proline residues; N803, asparagine residue; HIF-1a, hypoxia-
inducible factor 1 alpha; FIH, factor inhibiting HIF; PHD, prolyl-hydroxylase domain; VHL, von 
Hippel-Lindau; CBP, CREB binding protein; HRE, hypoxia responsive enhancer elements. Image 
taken from: “Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple 
myeloma, Borsi E., Translational Research, 2014”. 
 
In most in vitro chronic hypoxia studies, HIF-1α subunit levels are increased and 
stabilized within few hours, but after few days decrease to lower expression 
levels. This is likely due to the HIF-1-mediated upregulation of PHD2, which 
retains enough activity to hydroxylate HIF-1α, resulting in its renewed 
degradation (21). Instead, cycling hypoxia results in an enhanced activity and 
stabilization of HIF-1α, which is at a much greater level than that in chronic 
hypoxia (22). This damaging phenotype, where HIF-1α is accumulated, is also 
associated with an increased resistance to radiotherapy and chemotherapy as well 
as increased metastatic potential (16). 
During hypoxia, HIFs supports and even enhances the metabolic reprogramming 
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of glycolysis through the upregulation of almost all glycolytic genes and the 
monocarboxylate transporters that export lactate. It has been shown to upregulate 
the expression of genes encoding glucose transporters 1 and 3, glycolytic enzymes 
such as hexokinase 1 and 3, aldolase A and C and glyceraldehyde-3-phosphate 
dehydrogenase-6. 
HIF transcription factors have also been shown to affect the function and stability 
of some oncogenes and tumor suppressor genes. Although one of the most studied 
oncogenes linked to HIF is p53, the relationship between HIF and p53 remains 
still discussed. Hypoxia has been shown to induce p53 stability in some 
conditions but the molecular mechanism is unclear (23). It appears that severity 
and duration of the hypoxic stimulus influence the hypoxia-induced differences in 
metabolism that are dependent on HIF during acute hypoxia, but engages p53-
mediated gene expression changes during chronic hypoxia (16).  
HIFs proteins, in particular HIF-1, also regulate a set of genes involved in 
extracellular matrix remodeling, migration and digestion of the basement 
membrane. This group includes vimentin, fibronectin, keratins, matrix 
metalloproteinase 2, cathepsin D that is associated with a concomitant loss of E-
cadherin, a crucial feature of epithelium mesenchyme transition (EMT). In this 
regard, the first evidence linking HIF to decreased expression of E-cadherin was 
demonstrated in ovarian carcinoma in 1999 when immunolocalization of nuclear 
HIF-1α showed a strong topological correlation with loss of E-cadherin (24).  
1.1.3 ROS production in tumor microenvironment 
ROS are a broad class of oxygen radical species that are produced in cells 
as a normal byproduct of metabolic processes. They are characterized by 
heterogeneous properties and have a plethora of downstream effects, 
depending on their concentrations. Under physiological conditions the 
continuous production and detoxification of cellular ROS lead to a tightly 
controlled and well-balanced redox status. On the other hand, an imbalance 
between ROS production and removal results in the accumulation of ROS in 
the cells and leads to oxidative stress. In order to maintain the redox balance, 
cells activate some ROS scavenging systems, mainly composed of antioxidant 
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enzymes and non-enzymatic ROS scavengers. Common enzymes that are 
involved in the detoxification process of ROS are superoxide dismutase, 
catalase, peroxiredoxins and glutathione peroxidases. For their reducing power, 
glutathione and NAD(P)H are the most well-known electrons donators (25). 
ROS and associated oxidative stress have been historically considered harmful to 
the cell as they can damage cellular DNA, oxidize fatty acids and aminoacids. The 
effects of these oxidation lead to tissue destruction associated with various 
diseases.  
Consequences of ROS production in cancer biology are pleiotropic and complex. 
Although higher ROS levels are related to cancer cell growth, angiogenesis and 
metastasis, their role in cancer cells is still disputed. It has been shown that ROS 
have mainly dual functions, cytotoxic or tumorigenic, depending on different 
types and levels of ROS (25). At low concentration, ROS seem to increase cell 
proliferation and survival through the post-modification of some kinases and 
phosphatases. Conversely, excessive ROS levels irreversibly damage the cellular 
macromolecular components and result in cell death. Furthermore, high ROS 
levels can mediate mobility and invasive properties of cancer cells, contribute to 
extracellular matrix remodeling, increase neo-angiogenesis and induce metabolic 
reprogramming of both cancer and stromal cells. 
TME is characterized by elevated ROS levels that trigger oxidative stress, deeply 
affecting tumor progression and metastasis. This condition can result from 
increased basal metabolic activity, mitochondrial dysfunction, peroxisome 
activity, uncontrolled growth factor of cytokines signaling, and oncogene activity, 
as well as from enhanced activity of known ROS sources as NADPH oxidase 
(NOXs), cyclooxygenases (COXs), or lipoxygenases (LOXs) (26,27). 
It is well accepted that ROS levels strongly increase during hypoxic exposure, 
mainly in chronic hypoxia ranges and reoxygenation periods that follow hypoxia 
(22). These events partially justify the different impacts of continuous and cycling 
hypoxia on a variety of parameters, such as angiogenesis, metastatic behavior and 
treatment responses. Mechanisms that mediate adaptation to burst of ROS lead to 
activate the detoxification systems with an increase of hypoxia-induced 
glutathione and NAD(P)H synthesis. These signaling pathways in TME, 
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contribute to render cancer cells even more resistant to a variety of stresses 
including anticancer drug exposure or mechanical forces when entering the 
bloodstream (13). Thus, within TME, both ROS production and detoxification are 
known to be critical to maintain the redox balance for the cancer cells viability 
(28).   
1.2 Tumor dormancy and the interplay with tumor microenvironment  
The development of metastasis rather than tumor itself is one of the major causes 
of death among cancer patients. In some instances, this occurs shortly after 
primary tumor detection and treatment because tumor cells are already expanding 
at the moment of the diagnosis. However, in many types of tumors, metastatic 
diseases occur years or decades after tumor resection. The appearance of tumor 
relapse after prolonged time is explained by the survival of disseminated tumor 
cells (DTCs) in a dormant state. These cells survive in a quiescent state and 
remain undetected for long periods, explaining the prolonged asymptomatic 
residual disease and treatment resistance.  
The period between primary tumor detection and metastatic relapse is often 
defined as tumor dormancy, a poorly understood stage in cancer progression in 
which cells are characterized by mitotic cycle arrest in G0/G1 phase and low 
metabolism (29). This state is reversible and under certain conditions, such as 
induction by growth factors, cytokines, nutrients, or chemical agents, the cells can 
re-enter in the cell cycle to proliferate again. 
Tumor dormancy results by tumor cell growth arrest (cellular dormancy) and by 
mechanisms that antagonize the expansion of a dividing tumor cell population 
(tumor mass dormancy) (Figure 3). The first one can occur when tumor cells enter 
a state of quiescence. In this regard, the absence of proliferation in dormant cells 
has been attributed to the up-regulation of cell cycle inhibitors such as p21 and 
p27. In contrast to single cell dormancy, in tumor mass dormancy, the cells 
usually divide but the micrometastatic lesion does not expand beyond a certain 
size because of either limitations in blood supply or an active immune system. It 
seems to be caused by a balance of cells proliferation and apoptosis, regulated by 
pro-angiogenic proteins and angiogenic inhibitors produced by tumor and stromal 
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cells, as well as immunological switches. This phenomenon is also termed 
angiogenic dormancy (30). According to this definition, Naumov et al. sustain 
that a failure to activate the angiogenic switch contributes to maintain a group of 
cells in a dormant state (31). Indraccolo et al. reported that a short-term 
perturbation in a transient angiogenic burst could be sufficed to interrupt tumor 
dormancy (32). In this regard, therapeutic strategies to target tumor vasculature, 
such as anti-VEGF drugs, are the current approaches to oppose dormant cells.  
Tumor mass dormancy can be also maintained by the immune system that 
controls and does not completely eliminate malignant tumor growth. This process 
is termed immunologic dormancy and given that tumor cells are inherently 
genetically unstable, the strong immune pressure placed on tumor cells in 
equilibrium makes them susceptible to acquire mutations that may allow for 
immune evasion. These adapted tumors frequently defects in antigen presentation, 
processing or both, through loss of MHC class I or latent membrane protein 
(LMP)-family molecules, rendering them undetectable by the adaptive immune 
system. They are also capable of establishing a global immunosuppressive state in 
the TME by secreting some cytokines, such as TGF-β and VEGF, or by recruiting 
immunosuppressive cell type, including T regulatory cells and myeloid-derived 
suppressor cells (MDSCs). These recruited cells contribute to the anti-
inflammatory cytokine production and suppress the anti-tumorigenic capacities of 
the other immune cell types. Once micrometastases overcome dormancy, they 
become receptive to signals and cell types within the TME to support their 
expansion. Thus, controlled immune activation, marked by an induction of T 
cells, is a promising avenue to force tumor dormancy (Figure 3) (30).   
To date, little is known regarding tumor dormancy and the biology of dormant 
cells. Nevertheless, it is clear that one major driving force for tumor dormancy is 
cellular environment, which poses a challenge to the cells regarding survival and 
proliferation. Indeed, cells enter or escape dormancy according to restrictive or 
permissive microenvironment, adapting themselves to better serve its needs. In the 
restrictive TME, one of the early responses of tumor cells is to reduce growth and 
the rate of oxygen consumption. Using immunocytochemical techniques, some 
researchers have demonstrated that hypoxic tumor cells are in a non- or slow-
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proliferating state and a majority of these cells are negative for proliferation 
markers, such as Proliferating Cell Nuclear Antigen (PCNA) or 
Bromodeoxyuridine (BrdU) (20).  
In according to these evidences, the link between cellular dormancy and TME is 
highlighted by the fact that if the dormant DTCs are originated from the hypoxic 
niche of the primary tumor, they may be already pre-programmed to be growth-
arrested and enter a dormant state before to reach other sites. On the other hand, 
the inductor of dormancy can be the restrictive microenvironment of the target 
organs where the DTCs arrive. However, whether hypoxia signaling prepares a 
“metastatic soil” in distant organs to remain in a prolonged state of dormancy is 
not well clarified. However, in several different types of cancers, the bone marrow 
is a common homing organ for DTCs. In most studies, DTCs are detected in the 
hypoxic regions of bone marrow and persist there over many years with the 
potential to recirculate into other organs. 
In order to find treatments to remove solitary dormant cells or dormant 
micrometastasis, the researchers need to understand which mechanisms are 
responsible for metastatic dormancy and what processes trigger dormancy escape. 
Next paragraph points out some aspects of the knowledge on the mechanisms 
underlying dormancy in cancer.  
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Fig. 3. An integrated view of cancer dormancy. Tumor cells that survive dissemination lodge in 
the target organ parenchyma. A. This new microenvironment most probably determines the fate of 
the disseminated tumor cells and could account for most of the dormancy time (cellular 
dormancy). If the cells are not genetically progressed it is possible that they are unable to grow 
autonomously or transduce growth signals from the microenvironment, instead entering a 
quiescence-like phenotype. Even with genetic alterations, stress and/or microenvironment signals 
might impose a growth-suppressive program. For tumor cells, a quiescent state might be a natural 
response to a microenvironment that lacks recruitment signals, tumor cells can fully progress into 
overt lesions. B. It is possible that before becoming overt lesions, dormancy might continue owing 
to the immune system preventing tumor expansion (immunologic dormancy). The immune system 
might prevent tumor mass expansion for long periods. C. Moreover, a tumor cell mass can enter 
angiogenic dormancy. Differentiated tissues can produce angiogenesis inhibitors to maintain 
tumor vasculature from expanding for long periods. However, it is still unclear how long this 
mechanism can be maintained in a genetically unstable proliferative tumor cell population, which 
probabilistically should be prone to accumulating new genetic alterations that activate the 
angiogenic switch. Image taken from: “Models, mechanisms and clinical evidence for cancer 
dormancy, Aguirre-Ghiso JA., Nat. Rev. Cancer, 2007”. 
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 1.2.1 Signaling mechanisms in tumor dormancy 
To date, several cancer cell-intrinsic pathways that lead to cellular 
dormancy have been described. The first signaling mechanism that has been 
connected with the cells proliferation and DTCs dormancy were the balance 
between the activities of the mitogen-activated protein kinases (MAPKs) ERK1/2 
and p38 (33).  In particular, the switch toward phosphorylation of ERK1/2 favors 
proliferation, while predominant phosphorylation of p38 lead to quiescence. It is 
now well accepted that in a permissive microenvironment, the interaction between 
DTCs and extracellular matrix as well as stromal cells results in the in activation 
of mitogenic signaling (high p-ERK/p-p38) that promote cell growth. Conversely, 
in restrictive microenvironment, where the activation of stress signaling occurs, 
low p-ERK/p-p38 ratio represents the molecular switch for induction of a 
prolonged phase of dormancy (34). The activities of these kinases were found to 
be driven by the interaction of urokinase-type plasminogen activator receptor 
(uPAR), α5β1 integrin, fibronectin focal adhesion kinase (FAK) and Src-kinases. 
It has been demonstrated that proliferating cells are characterized by high 
expression of uPAR that lead to activation of Src-kinase resulting in the ERK1/2 
phosphorylation. Increased level of fibronectine also results in ERK1/2 
phosphorylation. Conversely, p38 phosphorylation is favored when uPAR 
expression is lost and fibronectin is absent (35-37).  
Recently, it has been shown that transforming growth factor β2 (TGFβ2) activates 
p38 in cancer cells disseminated to bone inducing dormancy. This correlates with 
up-regulation of the proliferation inhibitor p27 and down-regulation of cyclin-
dependent kinase 4 (CDK4). In this regard, an up-regulation of TGFβ2 and p27 
expression induced by hypoxia has been shown in dormant cancer cells, 
confirming a key role of hypoxia on dormancy (38). 
Moreover, phosphorylation of p38 leads to the activation of the unfolded protein 
response (UPR) pathway, which promotes cells survival and dormancy. Some 
studies from Aguirre-Ghiso laboratory highlight that, although all the three 
sensors of UPR, PERK, ATF6, IRE1 are activated in dormant human epidermoid 
carcinoma HEp3 cell, only PERK activation contributes towards the growth arrest 
of cells (35,39-41). This occurs by attenuating translation of G1-S transition 
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regulators such as cyclin D1, D3 and CDK4. On the other hand, the activation of 
both ATF6 and IRE1 are required for the basal adaptation and cell survival in 
restrictive microenvironment. This occurs in part via the ATF6 mediated Rheb 
induction and a strong inhibition of mTOR signaling (Figure 4) (42). 
 
 
Figure 4. Signaling mechanisms in response to TME. In a permissive microenvironment (right), 
interactions with the ECM, and stromal cells, allow to DTCs to adapt and integrate growth-
promoting signals and activate the mitogenic signaling (high p-ERK/low p-p38 ratio). Conversely, 
in restrictive microenvironment (left), the loss of surface receptors or the interaction with non-
growth-permissive ligands result in activation of stress signaling (low p-ERK/high p-p38 ratio) 
inducing both dormancy and survival signals. Activation of p38 induces G0/G1 arrest that is 
mediated by DEC2 e NDRG1, which control the expression of regulators of the cell cycle such as 
p21 and p27. Furthermore, phosphorylated p38 induces an ER stress response that coordinates 
growth arrest and survival through the activation of PERK. It leads to the downregulation of cyclin 
D1/D3 and CDK4 and to the induction of dormancy. ATF6 and IRE1 contribute to DTCs 
dormancy by promoting survival. ■ Three yellow squares indicate UPR. Image modified from: 
“Regulation of tumor cell dormancy by tissue microenvironmentsand autophagy”, Sosa M.S. et 
al., Adv. Exp. Med. Biol., 2013.   
 
 
Recently, it has been demonstrated the key role of the suppression of PI3K/AKT 
pathway in the induction of tumor dormancy as well as in the survival 
disseminated tumor cells (34). PI3K/AKT signaling regulates cell proliferation, 
survival and metabolism in cancer cells and it is frequently constitutively 
activated in multiple human cancers (43). Under prolonged lack of nutrients, the 
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suppression of AKT activity is necessary for preserving the energy source, 
decreasing energy demand and activating a strategy of cancer cells to survive in a 
chronically deteriorated microenvironment (44). The mechanism by which AKT 
activity is suppressed is not completely understood. It may involve different steps 
in the PI3K/AKT signaling such as inappropriate activation of receptor tyrosine 
kinase (RTK), inactivation of upstream kinases, i.e. PI3K, activation of 
phosphatase PTEN  or/and inactivation of mTORC1 (Figure 5). PI3K/AKT axis 
directly inhibits glycogen synthase kinase 3-beta, which normally suppresses 
proliferation, and activates the canonical cell cycle pathway. Conversely, the 
suppression of AKT that occurs in dormant state, allows to activate both CDKs 
inhibitors p21 and p27 that arrest cell cycle, and the autophagic machinery that 
protects cells during starvation or stress condition (45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5 Prototypic mechanisms of Akt regulation. The lipid kinase PI3K is activated in response 
to mitogenic signals and phosphorylates the phosphoinositides PI(4)P and PI(4,5)P2 at their D3 
position, generating PI(3,4)P2 and PI(3,4,5)P3, respectively. The tumor suppressor PTEN opposes 
this activity of PI3K. PI(3,4)P2 and PI(3,4,5)P3 bind to Akt and PDK1, promoting their 
translocation to the cell membrane. Akt is then activated by sequential phosphorylation of T308 
and S473 by PDK1 and mTORC2, respectively. Akt, in turn, activates mTORC1 indirectly by 
phosphorylation and inactivation of TSC2, which suppresses the activity of the Rheb GTPase, an 
activator of mTORC1. Akt also directly activates mTORC1 through phosphorylation of PRAS40, 
a component of mTORC1. Image taken from: “Akt-dependent and -independent mechanisms of 
mTOR regulation in cancer, Memmott RM et al, Cell Signal, 2009”. 
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1.3 Cancer stem cells in tumor microenvironment  
Recent studies indicate the presence of a small, intra-tumoral subpopulation of 
tumor-initiating cancer cells with deregulated stem-cell-like properties that enable 
them to be resistant to conventional therapies. These tumorigenic cancer cells, 
called cancer stem cells (CSCs), may be the linchpins of disease recurrence and 
may significantly contribute to metastasis (2). 
Specifically, CSCs exhibit a functional stemness signature comprising self-
renewal and ability to differentiate into multiple cancer cells (63). Self-renewal is 
a characterized mitotic cell division in which a stem cell originates one or two 
undifferentiated cells perpetuating the stem cell pool. On the other hand, the stem 
cells differentiate into more specialized cell types generating all the diverse 
cellular phenotypes of the primary lesion (2). Evidences support the vital role of 
this subset of cells in initiation and maintenance of a tumor in addition to their 
capability to dictate invasion, metastasis, heterogeneity, and therapeutic 
resistance. Therefore, the identification and isolation of these CSCs using putative 
surface markers have been a priority of research in cancer. However, definition of 
specific CSCs surface markers in all cancer types requires further investigations. 
It is clear that heterogeneity among tumors renders it difficult to discover unique 
markers (64).  
There are some putative stem cell markers that are in major use for identification 
and isolation of CSCs from different solid tumors (65-67) Even if every marker 
shows independent expression, it seems to be a co-expression of surface markers 
in CSCs, debatable in several cancer types. Indeed, CD44 and CD24 have been 
used extensively in combination or with other putative markers (CD133, CD166, 
EpCAM) to isolate CSCs from solid tumors (64). Abraham et al. demonstrated 
that the majority of breast human tumors tissue (78%) displayed ≤10% CD44+/CD24−/low 
cells and the remainder contained >10%. (68). 
CSCs selection and evolution are influenced by TME that provides a breeding 
ground to maintain a more stem-like and undifferentiated phenotype. For instance, 
hypoxia exerts a selective pressure on the CSCs population contributing directly 
to the development of more aggressive cancer cells and resistance to therapies 
(69,70). Recently, it has been demonstrated that prolonged hypoxia exposure 
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results in the induction of genes essential for stem cell function such as Oct4, 
Nanog and c-Myc. These genes are regulated by HIFs, in particular the isoform 
HIF-2α, which is specifically involved in the self-renewal and multipotency of 
CSCs. Molecular database analyses revealed that HIF-2α expression correlates 
with poor outcome of patients with metastasis and represent a promising target for  
the eradication of CSCs in cancer therapy (71). 
1.3.1 Tumor dormancy and cancer stem cells 
 There is a tight and complex relationship between stemness and dormancy 
even if the ability of CSCs to proliferate and initiate robust tumor outgrowth, 
seems to be incompatible with a cancer dormant state. Elegant studies provided 
strong evidences for the existence of dormant cells as a subpopulation of CSCs in 
different tumors such as breast, colon, pancreas and ovary (72-77). Nevertheless, 
it is important to note that not all dormant cells have the stem like properties of 
self-renewal and differentiation (78). 
Unlike dormant tumor cells that can remain quiescent for several years, it is not 
clear if CSCs undergo so long phase of quiescence (69). However, it is well 
described that these dormant CSCs exploit phases of cellular dormancy to ensure 
tumor maintenance and survival in harmful TME, including growth-inhibitory 
niches and cytotoxic mileus.  
It is clear from the previous discussion that hypoxic TME maintains an 
undifferentiated and quiescent state of CSCs and, since hypoxia promotes tumor 
dormancy, it could be one of the key links between the dormancy and the 
stemness. How the hypoxia triggers CSCs populations towards quiescence is still 
unclear even if some improvements are carried out. It has been demonstrated that 
slow-cycling CSCs are more likely localized in the low oxygen area of the tumor, 
away from the blood vessels whereas the fast-cycling cells with limited self 
renewal capacities, reside in areas much closer to the vasculature (79). 
Moreover, several studies have unraveled intriguing parallels between the 
mechanisms regulating CSCs behavior and angiogenic control of tumor 
dormancy. While CSCs might survive in the angiostatic environments associated 
with dormancy, they also promote cancer vascularization in settings of tumor 
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outgrowth (80,81). Since CSCs own the ability to promote tumor progression by 
triggering angiogenic responses, they are likely to represent the dormant tumor 
populations ultimately responsible for delayed cancer recurrences (79).  
Another direct link between CSCs and dormant tumor populations is their 
converging to survive cancer therapy. Indeed, dormant cells are often spared by 
current treatment modalities, as determined in both animal models and clinical 
disease (82,83). Similarly, CSCs frequencies are enhanced in metastatic tumor 
recurrences post-therapy compared to those in pre-therapy samples. Importantly, 
therapeutic refractoriness of tumor dormant cells is attributable to several 
resistance mechanisms also intrinsic to the CSCs compartment, including 
impairment of cancer apoptotic pathways, alterations of cell cycle checkpoints, 
and reduced drug accumulation. (84).  
Taken together these findings highlight the critical importance of TME in the 
biology of CSCs that creates a strong relationship with tumor dormancy. 
However, in light of the intriguing discussion between CSCs biology and the 
mechanisms controlling tumor dormancy, insights from CSCs biology could help 
the future research on tumor dormancy. 
1.4 Autophagy 
Autophagy, or type II programmed cell death, is a catabolic process, 
evolutionarily conserved and genetically controlled, whereby cells self-digest 
intracellular organelles to remove those with compromised function and to 
maintain cell homeostasis. However, autophagy can also be considered a 
temporary survival mechanism during periods of starvation where self-digestion 
offers an alternative energy source and may facilitate the disposal of unfolded 
proteins under stress conditions. The catabolic function provided by autophagy is 
thereby suppressed once the external nutrient supply is adequate to support 
cellular metabolism. Besides starvation, autophagy can be also activated by other 
physiological stress stimuli, such as hypoxia, endoplasmatic reticulum stress, high 
temperature, hormonal stimulation or pharmacological agents (85) (Figure 6). 
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Fig. 6 The process of autophagy leads to the degradation of cargo.  The blue double-
membraned vesicle, autophagosome; red vesicle, lysosome; blue shaded oval structure, nucleus. 
Cargo in the autophagosome is represented by the following: mitochondria in yellow, protein 
aggregates in black and red, and other cargo generally represented in green and purple Image taken 
from: “Autophagy and tumor metabolism, Kimmelman AC et al, Cell Metabolism, 2017”. 
 
 
Depending on the mode of cargo delivery to lysosome, autophagy can be 
subdivided into three subtypes: chaperon-mediated autophagy, microautophagy 
and the most studied process named macroautophagy (86). Chaperone-mediated 
autophagy involves the direct translocation of cytosolic proteins across the 
lysosomal membrane, by molecular chaperones (e.g., the 70 kDa heat shock 
cognate protein, Hsc70). Microautophagy involves inward invagination of 
lysosomal membrane, which delivers a small portion of cytoplasm into the 
lysosomal lumen. Macroautophagy is the most efficient autophagic clearance 
mechanism and the most common type of autophagy, therefore, hereafter 
macroautophagy will be referred to as autophagy. Macroautophagy is a process 
conserved by yeast to mammals and is mediated by a double-membrane special 
organelle termed autophagosome. Upon induction, a small vesicle (phagophore) 
elongates and encloses a portion of cytoplasm, which results in the formation of 
the autophagosome. Then, the outer membrane of the autophagosome fuses with a 
lysosome to form an autolysosome, leading to the degradation of the enclosed 
materials together with the inner autophagosomal membrane (Figure 7). 
Aminoacids and other small molecules that are generated by autophagic 
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degradation are delivered back to the cytoplasm for recycling or energy 
production (87). Specifically, the process of autophagosome formation involves 
two major steps, nucleation and elongation of the isolation membrane, in which 
different proteins, such as the products of AuTophaGy-related (Atg) genes and 
microtubule-associated protein light chain 3 (LC3) are involved (88).  LC3 is one 
of the best characterized protein on autophagosome, and therefore, it serves as 
widely used marker of autophagy (89). It is expressed in cells as a full-length 
cytosolic protein that, upon autophagy induction is proteolytically cleaved, to 
generate LC3-I that is conjugated with phosphatidylethanolamine and forms LC3-
II (90-92).  
 
 
 
 
Fig. 7 Macroautophagy steps. Macroautophagy starts with the de novo formation of a cup-
shaped isolation double membrane that engulfs a portion of cytoplasm. Colored balls indicate 
proteins (Atgs, etc) involved in the process. The image is taken from: “Autophagy: molecular 
machinery, regulation, and implications for renal pathophysiology”, Periyasamy-Thandavan et al, 
American Journal of Physiology - Renal Physiology, 2009”. 
 
 
Among the numerous components involved in the regulation of autophagy, the 
Mammalian Target of Rapamycin (mTOR) is now recorgnized as sensor that 
coordinately regulates the balance between growth and autophagy in response to 
cellular physiological conditions and environmental stress (93). mTOR is a 
serine/threonine protein kinase that belongs to the phosphatidylinositol kinase-
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related kinase (PIKK) family. The inhibition of mTOR activity, through Akt and 
MAPK signaling, under nutrient starvation, induces autophagy as well as negative 
regulation of mTOR, through AMPK and p53 signaling, promotes it (94). 
Under physiological conditions, autophagy has a number of other vital roles such 
as maintenance of the aminoacid pool during starvation, prevention of 
neurodegeneration, antiaging function, clearance of intracellular microbes and 
regulation of innate and adaptive immunity (86,95). 
In addition to the physiological roles of autophagy, many reports describe its 
controversial involvement in the genesis and the progression of cancer (96-98).  
Indeed autophagy acts either as a tumor suppressor, by preventing the 
accumulation of damaged proteins and organelles, or as a mechanism of cell 
survival that promote and maintain the growth of established tumors (99).  
 
1.4.1 Autophagy sustains survival of dormant cancer cells 
 A potential role of autophagy in dormancy was originally evidenced in C. 
elegans during a dormancy-like state, where larvae are exposed to hostile 
microenvironment. In this model, C. elegans activated autophagy that could 
promote survival during quiescent states (100).  
Since autophagy is activated in response to changes of the microenvironment, it 
could be interesting to investigate the mechanisms that induce autophagy and 
allow to the survival and the maintenance of the dormant state in tumor cells. 
Although the efforts to show through in vitro or in vivo models, the role of 
autophagy in dormancy and the mechanisms that are activated during this state 
remain largely discussed. However, studies in models of breast cancer cells 
suggest that the decreased mitogenic signaling of β1-integrin in dormancy may 
stimulate autophagy (101). Moreover, it has been shown that dormant cancer cells 
activate p27 that is involved in cell cycle arrest and directly induces autophagy to 
facilitate cells survival in response to growth factor withdrawal (102,103).  
It would be critical to determine whether autophagy plays a dormant or survival-
inducing role, or both, in quiescence tumor cells. If autophagy induces a pro-
survival state, then strategies to block it could eradicate dormant cells. In case that 
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it contributes to both quiescence and survival, then more detailed analysis of these 
pathways would be required to reveal ways to inhibit only the survival signals 
without interrupting quiescence (104). 
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2. AIM OF THE THESIS  
The hypoxic tumor microenvironment has been recognized as a cause of 
malignancy or resistance to various cancer therapies. However, the effect of a 
chronic exposure of the cells to hypoxia and the following reoxygenation cycles 
remain elusive. Although most of the tumor cells die in chronic hypoxia, some of 
them can survive for more than several days in a quiescent state. This dormant 
state is reversible, with tumor cells recovering the ability to self-renew once 
closed vessels reopen or new vasculatures reach the hypoxic area. Because 
dormant tumor cells may be the founders of metastasis, one hypothesis is that 
these cells share stem cell-like characteristics that may be responsible for their 
long half-lives. 
An understanding of the regulatory machinery of tumor dormancy is essential for 
identifying early cancer biomarkers and could provide a rationale for the 
development of novel agents to target dormant tumor cells population. The lack of 
established in vitro models of tumor dormancy represents the major factor that 
hampers the understanding of dormant cells response. Indeed, the majority of in 
vitro hypoxia studies have been carried out exposing cell lines to acute hypoxia 
(3-24 h), whereas only few reports of chronic hypoxia have been published. 
Therefore, the aim of the thesis is to establish and characterize a new in vitro 
model of cell dormancy using hypoxia/reoxygenation cycles and culturing the 
surviving cells in chronic hypoxia condition. 
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3. MATERIALS AND METHODS 
3.1 Cell lines and cells culture 
Human breast cancer cell lines MDA-MB-231, MDA-MB-468, T47D, and MCF-
7 were purchased from American Type Culture Collection. All the cell lines were 
cultured in DMEM (LifeTechnologies) supplemented with 10% FBS, 100 UI/mL 
penicillin, 100 μg/mL streptomycin, and 40 μg/mL gentamycin (Life 
Technologies) in a 5% CO2 atmosphere at 37°C. Hypoxic culture was achieved by 
incubating cells with 1% O2 and 5% CO2 in a Multigas Incubator (RUSKINN 
C300, RUSKINN Technology Ltd) in DMEM without sodium pyruvate and 
supplemented with 25 mM HEPES, 10% FBS, 100 UI/mL penicillin, 100 μg/mL 
streptomycin, and 40 μg/mL gentamycin. After some hypoxia/reoxygenation 
cycles, the surviving cells were cultured under 1%O2 athmosphere for at least 3 
months. The hypoxia-resistant MDA-MB-231 cell line was designed as chMDA-
MB-231.  
3.2 Morphological analyses of dormant cells and tumorspheres 
Approximately 6 x 104 MDA-MB-231 and chMDA-MB-231 cells were seeded on 
a 4-chamber slide, with 13 mm glass bottom (IbidiGmbH). After 24 h, cells were 
incubated for 5 min with a staining solution made of CellMaskDeep Red 
(LifeTechnologies) 1:1000 cell media without serum. Before the acquisition, the 
medium was replaced with a special medium without phenol red (DMEM/F12 
NoPhenolRED, LifeTechnologies) to avoid any interference with the ﬂuorescence 
signal.  
The tumospheres deriving from 60 wells of a coated 96 well-plate were gently 
collected by a p1000 tip with a cut extremity and seeded on a 4-chamber slide. 
After 24 h, cells were incubated for 60 min with a staining solution made of 
CellMaskDeep Red 1:1000 (LifeTechnologies) and Hoescht 1:1000 
(LifeTechnologies) in DMEM/F12NoPhenolRED. Cell images were captured 
using a confocal laser-scanning ﬂuorescence microscope Leica SP5 (Leica 
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Microsystem) at 63x magniﬁcation and processed using Adobe Photoshop and 
ImageJsoftwares (Rasband, W.S., ImageJ, http://rsb.info.nih.gov/ij/, 1997–2008). 
3.3 Cells viability 
The viability of MDA-MB-231 and chMDA-MB-231 cells were evaluated with a 
0.1% Trypan Blue exclusion test using a Countess Automated Cell Counter 
(LifeTechnologies). 
3.4 Immunophenotype 
Cells were harvested, washed in phosphate buffer saline (PBS) and stained with 
anti-human CD326/ESA-FITC, CD24-FITC (MiltenyiBiotec), CD44-PE (BD 
Pharmingen). After incubation at room temperature for 15 min, cells were washed 
in PBS, acquired on aFACScan cytometer (Becton Dickinson) and analyzed by 
FlowJo9.3.3 software (Tree Star). Data were expressed as the difference of 
Median Fluorescence Intensity (MFI) between stained and unstained cells. 
3.5 Cell cycle 
Cells were incubated with 10 mM Vybrant DyeCycle orange stain 
(LifeTechnologies) for 15 min and with 1 mM Sytox Blue dead Cell stain 
(LifeTechnologies) for additionally 15 min to exclude dead cells from cytometric 
analysis. 
3.6 Cell proliferation 
Cells were labeled with the amine-reactive dye 5,6-carboxyﬂuor-escein diacetate, 
succinimidyl ester (CFSE), as described previously (105).This dye is incorporated 
into cells and divided equally into daughter cells during proliferation. Thus, cells 
proliferation can be determined by measuring the MFI by ﬂow cytometry on a 
FACS scan ﬂow cytometer. Brieﬂy, they were resuspended at a ﬁnal 
concentration of 107cells/mL in PBS-5% FBS and incubated with 5 mM CFSE for 
5 min at room temperature. The reaction was stopped by washing twice with PBS-
5% FBS. Cells were replated at 106 cells/mL in complete medium in normoxic 
andhypoxic conditions. An aliquot of cells was harvested every 24 h for 3 days, 
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added with TO-PRO-3 (LifeTechnologies) and subjected to ﬂow cytometry 
analysis. 
3.7 Measurement of glucose, pyruvate, and lactate concentration 
After 3–5 days of culture under normoxic or hypoxic conditions, the medium of 
MDA-MB-231 and chMDA-MB-231 cells were harvested and cells were counted. 
The concentration of glucose and lactate in the media was measured by using the 
glucose assay kit (CaymanChemical) and the lactate assay kit (Megazyme 
International), respectively, according to the manufacturer’s instructions. To 
measure the amount of pyruvate produced, 5–50 L of medium were added to 370 
mM Tris–HCl pH 8, containing 350 mM NADH and 3 mg of LDH (Sigma), to a 
ﬁnal volume of 300 L. The total change of the absorbance at 340 nm was 
measured and using the molar extinction coefﬁcient of NADH at 340 nm (6,220 
M/cm), the moles of NADH oxidized, that are equal to the moles of pyruvate 
produced, were calculated. 
3.8 Glutathione content quantification 
The intracellular GSH concentration was measured by endpoint 
spectrophotometric titration on a Jasco V/550 spectrophotometer (JASCO) using 
the 5,50-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman’sreagent) (106). Brieﬂy, 
MDA-MB-231 and chMDA-MB-231 cells were lysed by freezing and thawing in 
100 mM sodium phosphate buffer, pH 7.5, containing 5 mM EDTA, (KPE 
buffer), and after centrifugation at 16,000 rpm for 10 min, total protein 
concentration was determined by Bradford reagent (Pierce) using bovine serum 
albumin as standard (107). The supernatants were deproteinized with 5% 
trichloroacetic acid. For [GSH] measurement, acidiﬁed clear supernatants were 
neutralized and buffered at pH 7.4 with 200 mM K2HPO4, pH 7.5. The reaction 
was then started by the addition of 60 mM DTNB and the increase inabsorbance 
at 412 nm was measured until no variation in absorbance was evident. The 
amount of total GSH was determined by comparison with GSH standard curve. 
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3.9 Detection of intracellular reactive oxygen species (ROS) 
a) CM-H2DCFDA staining: MDA-MB-231 and chMDA-MB-231 cells were 
resuspended in HBSS (LifeTechnologies) at 3x105 cells/mL and loaded with 2.5 
μM of the cell-permeant probe 5-(and-6)-chloromethyl-2'7'- 
dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA; Molecular 
Probes) for 1 h at 37°C, as previously described (108). ROS generation was 
evaluated in flow cytometry (Becton Dickinson) by measuring the green 
fluorescence signal (Fl-1) of CM-H2DCFDA that occurs after removal of the 
acetate groups by intracellular esterases and oxidation by free radicals. Data were 
analyzed by FlowJo 9.3.3 software.  
b) Mitosox staining: Approximately 6 x 104 MDA-MB-231 and chMDA-MB-231 
cells were seeded on a 4-chamber μslide, with 13 mm glass bottom (Ibidi GmbH). 
After 24 h, cells were incubated for 30 min with a staining solution made of 
Mitosox 1:1000 (LifeTechnologies), Mitotracker greenFM 1:5000 
(LifeTechnologies) and Hoescht 1:1000 (LifeTechnologies) in medium without 
FBS. Before the acquisition, the medium was replaced with a medium without 
phenol red (DMEM/F12 NoPhenolRED, LifeTechnologies) to avoid any 
interference with the fluorescence signal. Cell images were captured using a 
confocal laser-scanning fluorescence microscope Leica SP5 at 63× magnification 
and processed using Adobe Photoshop and ImageJ softwares (Rasband, W.S., 
ImageJ, http://rsb.info.nih.gov/ij/, 1997–2008). 
3.10 Western Blot 
Cells were homogenized at 4°C in 20 mM HEPES, pH 7.4, containing 420 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Nonidet-P40 (NP-40), 20% glycerol, 
protease cocktail inhibitors (GE Healthcare, Amersham) and phosphatase cocktail 
inhibitors. Protein concentration was measured by Bradford reagent using bovine 
serum albumin as standard (107). Protein extracts (50 μg/lane) were resolved by 
SDS PAGE electrophoresis and transferred to PVDF membrane (Immobilon P, 
Millipore). Immunoblotting assays  were carried out by standard procedures using 
anti-LC3, anti-p(Thr180/182)-p38, anti-p38, anti-p(Ser)-AKT, anti-AKT and anti-
P70S6 kinase antibodies (Cell Signaling Technology), anti-STAT1, anti-STAT3, 
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anti-p53, anti-p(Thr202/Tyr-204)-ERK and anti-ERK antibodies (Santa Cruz 
Biotechnology), anti-HIF1α antibody (BD bioscience) anti-actin antibody 
(Millipore), anti-HIF2α antibody (Novus Biologicals). After washing, membranes 
were developed using anti-rabbit or anti-mouse IgG peroxidase-conjugated 
antibodies (Cell Signaling Technology) and chemiluminescent detection system 
(Immun-Star™ WesternC™ Kit, Bio-Rad). Blotted proteins were detected and 
quantified using the ChemiDoc XRS Imaging System (Bio-Rad).  
3.11 Real time PCR  
Cellular RNA was extracted by PureLink Total RNA kit (AmbionTM) according 
to the manufacturer's instructions. Total RNA was quantified at 260/280 nm, and 
the integrity of the samples was checked by 1% agarose gel electrophoresis. 
Aliquots corresponding to 1µg of total RNA were reverse transcribed by using the 
SuperScript Vilo cDNA synthesis kit (InvitrogenTM) following the manufacturer's 
protocol. Aliquots of the cDNAs (corresponding to 50 ng of the original RNA) 
were subjected to real-time PCR with the QuantiTect SYBR Green PCR Kit  
(Qiagen,) following the manufacturer's instructions. Bioinformatically validated 
primer sets for real-time PCRs were purchased by Qiagen (QuantiTect Primer 
Assays: Hs_RRN18S_1_SG for 18S, Hs_PGK_1_SG for PGK, 
Hs_SLC2A1_1_SG for GLUT1 and Hs_GADPH_2_SG for GAPDH). 18S rRNA 
was used as the housekeeping gene for sample normalization and was amplified in 
separate tubes within the same run. The PCR was performed with an initial pre-
incubation step for 15 min at 95°C, followed by 45 cycles of 94°C for 15 s, 
annealing at 55°C for 30 s, and extension at 72°C for 30 s. The specificity of the 
amplified products was monitored performing melting curves at the end of each 
amplification reaction. All amplicons generated a single peak, thus reflecting the 
specificity of the primers. Real-time PCR was performed using the Rotor-Gene 
6000 (Corbett Cambridgeshire, UK) and data analysis was conducted using the 
Rotor-Gene Software. Data were normalized to 18S and sample expression levels 
are shown as percentages of the internal control gene. Experiments were repeated 
at least three times. 
Materials and methods 
 
 35  
3.12 Detection of autophagic markers 
a) Acridine orange  staining. Approximately 6 x 104 MDA-MB-231 and chMDA-
MB-231 cells were seeded on a 4-chamber µslide, with 13 mm glass bottom (ibidi 
GmbH, Germany). After 24 h cells were rinsed in phosphate buffer saline (PBS) 
and stained with acridine orange (AO) (1:1500 in PBS). Cell images were 
captured immediately by using a confocal laser-scanning fluorescence microscope 
Leica SP5 (Leica Microsystem) at 63× magnification and processed using Adobe 
Photoshop and ImageJ softwares (Rasband, W.S., ImageJ, 
http://rsb.info.nih.gov/ij/, 1997–2008).  
b) Monodansylcadaverine staining and autophagosome formation assay. MDA-
MB-231 and chMDA-MB-231 cells were incubated with the fluorescent probe 
monodansylcadaverine (MDC, Sigma) a selective marker for acidic vesicular 
organelles, such as autophagic vacuoles. Briefly, cells were seeded in 96-well 
plates (3 × 104 cells/well) and after 24 h were incubated in culture medium 
containing 50 μM MDC at 37 °C for 15 min. Cells were then washed with Hanks 
buffer (20 mM HEPES pH 7.2, 10 mM glucose, 118 mM NaCl, 4.6 mM KCl, and 
1 mM CaCl2) and fluorescence was measured using a multimode plate reader 
(Ex340nm and Em535nm) (GENios Pro, Tecan). The values were normalized for cell 
proliferation by Crystal Violet assay. 
c) LC3-II. The presence of lipidated LC3-II isoform was analysed by Western 
Blot as described above using mouse anti-LC3I/II antibody that detects 
endogenous levels of LC3B isoforms I and II.  
3.13 Statistical analysis 
Data reported are the means ± S.D. of a least three independent experiment. 
Statistical analysis were performed by one-way analysis of variance (ANOVA) 
with Bonferroni test. P value ≤ 0.05 was indicated as a statistically significant. 
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4. RESULTS 
4.1 Survival of the cells under chronic hypoxia 
In order to establish a new in vitro model of breast cancer dormancy, we cultured 
four human breast cancer cell lines in 1% O2 atmosphere: MDA-MB-231, MDA-
MB-468, T47D and MCF-7. The cells were exposed to hypoxia for 1-7 days and 
then the surviving cells were reoxygenated for 1-3 weeks depending on the rescue 
of the cells and their proliferation rate. In our hands, only MDA-MB-231 cells 
were able to recover their proliferation rate and grow until the confluence. Then, 
MDA-MB-231 cells were exposed to repetitive cycles of hypoxia/reoxygenation. 
We set up the hypoxia/reoxygenation conditions regarding the number of cycles 
and exposure time.  
The optimized procedure included exposure of MDA-MB-231 cells up to 7 days 
to hypoxia and reoxygenation of the surviving cells for 7-10 days depending on 
their viability. After reoxygenation and growing, we exposed the cell line again to 
a second round of hypoxia, and found an increase in viability. After three rounds 
of hypoxia and oxygenation, the cells, designed as chronic hypoxia resistant 
MDA-MB-231 (chMDA-MB-231), were able to stably grow in 1% O2 hypoxia 
even if with a decreased proliferation rate. ChMDA-MB-231 cells were cultured 
under hypoxia for at least 3 months. 
Cells cycle analysis revealed that the new established hypoxia-resistant chMDA-
MB-231 cells were accumulated in G0/G1 phase and the percent in G2/M phase 
was drastically reduced (Figure 9A). 
Analysis of CFSE dilution showed a lesser decrease of fluorescence 
corresponding to higher concentration of the probe in chMDA-MB-231 after 24, 
48, and 72 h of culture under hypoxia respect to MDA-MB-231 in normoxia 
conditions. These data indicate that chMDA-MB-231 cells have a lower 
proliferation rate than the parental ones (Figure 9B). 
The arrest in G0/G1 phase and the low proliferation rate were reversible. Indeed, 
once replaced into fresh medium and re-oxygenized the cells, designed as reverted 
chronic hypoxia resistant MDA-MB-231 (RchMDA-MB-231), showed a recovery 
of the proliferation rate in 2 weeks (Figure 9). 
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Fig. 9 MDA-MB-231 cell line can survive chronic hypoxia entering into dormant state (A) 
Right. Flow cytometry analysis of cell cycle in MDA-MD-231 cells and in chMDA-MB-231. The 
cells were stained with 10 μM Vybrant DyeCycle orange and with 1 μM Sytox Blue (to exclude 
died cells from analysis). The cell cycle of chMDA-MB-231 reoxygenated in fresh medium 
(RchMDA-MB-231) was analyzed too. Left. Statistical analysis of the cell cycle phases. *P < 0.01 
(B) Right. Overlay histogram of the daily CFSE fluorescence intensity in the TO-PRO-3neg 
population. In MDA-MB-231 cells, CFSE is diluted among the daughter cells and fluorescence 
intensity decreases day by day. In chMDA-MB-231 cells, a lesser dilution of CFSE indicates 
decreased cell division. In RchMDA-MB-231 cells, the pattern of CFSE dilution is similar to that 
of MDA-MB-231 cells. Left. Plot of the daily percentage of CFSE fluorescence intensity as respect 
to time 0 in each condition (MFI ± SE, P < 0.01).  
Representative results or means ± SE of at least four experiments are depicted. 
 
 
Furthermore, a morphologic analysis of chMDA-MB-231, stained with the plasma 
CellMask dye, was performed by live confocal microscope. These cells displayed 
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a longer and a more fibroblastoid shape and higher cellular volume than the 
parental cells (Figure 10). 
Fig. 10 Confocal microscopy of MDA-MB-231 and chMDA-MB-231 after CellMaskDeep 
staining. Scale bar 10 μm. 
 
Differently from the parental cells, chMDA-MB-231 cells viability was less 
affected by doxorubicin, one of the most effective agents in the treatment of breast 
cancer patients (Figure 11). 
 
Fig. 11 Cell viability of MDA-MB-231 and chMDA-MB-231 cells after 24 h treatment with 
doxorubicin. ChMDA-MB-231 cells show a higher chemoresistance than the parental cells 
(EC50 = 0.25 μg/ml ± 0.05, MDA-MB-231; EC50 = 2.00 μg/ml ± 0.15, chMDA-MB-231). 
Representative results or means ± SE of at least four experiments are depicted. 
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All together, these results indicated that chMDA-MB-231 cells reversibly entered 
a dormant status under prolonged hypoxia. 
In order to investigate the molecular switch of dormancy induction in MDA-MB-
231 under hypoxia, we cultured cells in 1% O2 until 7 days. Western Blot analysis 
of the phosphorylation state of p38 and ERK1/2 revealed that p-p38 increased 
after 3 days of culture in hypoxia reaching high after 7 days while p-ERK level 
remained stable at all time points examined. The densitometric analysis showed 
that the ratio of p-ERK/p-p38 in MDA-MB-231 cells cultured in hypoxia was 
reduced as compared to MDA-MB-231 cells in normoxia starting from 7 days 
(Figure 12). 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
Fig. 12. Effect of chronic hypoxia on phosphorylation of ERK and p38 in MDA-MB-231. (A) 
Western Blot analysis shows that chronic hypoxia time-dependently triggers Thr/Tyr 
phosphorylation of p38. This protein was not phosphorylated when cells were cultured under 
normoxia (N). (B)  ERK phosphorylation state is not modified in MDA-MB-231 cells cultured 
under 1% O2 at all the indicated time. (C) The densitometric analysis of each Western Blot was 
performed  by QuantityOne software. The bars represent the ratio between phosphorylation of 
ERK, normalized on total ERK protein, and phosphorylation of p38, normalized on total p38 
protein. The images are representative of four independent experiments. 
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4.2 Analysis of redox state under chronic hypoxia 
In order to evaluate the redox status of the cells under chronic hypoxia, measure 
of ROS and GSH production were performed in chMDA-MB-231.  
chMDA-MB-231 cells loaded with CM-H2DCFDA, a specific cell-permanent 
ROS indicator, exhibited an increase of fluorescence as respect to the parental cell 
line (MFchMDA-MB-231= 1344 ± 541 vs MFIMDA-MB-231= 331 ± 71, Figure 13A). 
These data indicated an enhancement of intracellular ROS in chMDA-MB-231. 
Moreover, the intracellular GSH concentration, measured by DTNB staining, was 
lower in chMDA-MB-231 cells than in parental ones (10,60 ± 2,00 nmoles/mg 
proteins vs 20,70 ± 1,50 nmoles/mg proteins, Figure 13B) 
At the same time, confocal live microscopy analysis revealed a marked increase of 
mitochondrial ROS production in dormant chMDA-MB-231 cells as indicated by 
the appearance of a red signal, originated by the oxidation of the MitoSOX red 
reagent, which co-localizes with that of the mitochondrial marker (MitoTracker) 
(Figure 13C).  
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Fig. 13. Evaluation of redox state under chronic hypoxia. (A) Flow cytometry analysis of ROS 
production in MDA-MB-231 and chMDA-MB-231 cells loaded with CM-H2DCFDA.The 
fluorescence increase in chMDA-MB-231 cells indicates a higher ROS production as respect to 
parental cells. (B) Spectrophotometric analysis of intracellular GSH concentration in MDA-MB-
231 and in chMDA-MD-231. The decrease of absorbance at 420 nm in chMDA-MB-231 cells 
indicates a lower GSH concentration as respect to parental cells. Bar graphs represent the 
mean ± SE. *P < 0.01. Representative results of at least four experiments are depicted. 
(C) Confocal live microscopy of MDA-MB-231 and chMDA-MB-231 after Mitosox, Mitotracker 
greenFM, and Hoescht staining. Merge and single channel images come from a single zplane. 
Scale bar 10 μm. The appearance of red signal in chMDA-MB-231 reveals an increase of 
mitochondrial ROS production. 
 
4.3 Evaluation of energy metabolism under chronic hypoxia 
We further assessed the status of energy metabolism of the cancer cells in the 
dormant state. We measured glucose consumption and pyruvate and lactate 
production in the supernatants of chMDA-MB-231 and MDA-MB-231. As 
expected, the metabolism of dormant cells was deeply attenuated compared to 
MDA-MB-231, since chMDA-MB-231 presented reduced levels of glucose 
consumed and pyruvate-lactate produced (Figure 14A). Moreover, under 
normoxic condition, the amount of lactate produced is 3.3-fold lower than that of 
pyruvate, while under hypoxic conditions the amounts of lactate and pyruvate are 
similar. These data suggest that under normoxia cells execute aerobic catabolism 
of pyruvate, while under hypoxia they change toward anaerobic lactic 
fermentation. 
Next, we analyzed the expression of HIF-1α, a master regulator of energy 
metabolism under hypoxia. HIF-1α induces the expression of some target genes 
that promote angiogenesis, glycolysis, cellular proliferation or inhibition and 
metastasis. In line with another study performed by Wang et al., MDA-MB-231 
cells constitutively expressed HIF-1α under normal oxygen conditions (109) while  
chMDA-MB-231 cells present a lower level of HIF-1α protein (Figure 14B). As 
expected, the expression of GLUT1, GAPDH, and PGK, three glycolytic genes 
regulated by HIF-1 decreased in chMDA-MB-231 as compared to MDA-MB-
231 (Figure 14C). 
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Fig. 14. Effect of chronic hypoxia on energy metabolism and protein expression in MDA-
MB-231. (A) Analysis of MDA-MB-231 and chMDA-MB-231 cells metabolism. The media were 
analyzed to define the amount of glucose consumed (□), pyruvate produced ( ), and lactate 
produced ( ). Bar graphs represent the means of glucose consumed ± SE of three independent 
experiments. *P < 0.01 versus normoxic condition. (B) Western blot analysis of various proteins 
expression in chMDA-MB-231 (ch) compared to MDA-MB-231 (N). Actin is used as control 
loading. The images are representative of four independent experiments. (C) Histograms of the 
analysis of GLUT1, GAPDH, and PGK gene expression in MDA-MB-231 in normoxic and 
hypoxic conditions by RT-PCR. (D) Western blot analysis shows that chronic hypoxia up-
regulated Thr phosphorylation of AMPK without affecting the total amount of AMPK in MDA-
MB-231. MDA-MB-231 cells cultured under normoxic condition were used as control (N). (E) 
Western blot analysis shows that chronic hypoxia up-regulated Ser phosphorylation of eIF2α (ch) 
without affecting the total amount of eIF2 in chMDA-MB-231. MDA-MB-231 cells cultured 
under normoxic condition were used as control (N). The images are representative of four 
independent experiments. 
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Since it has been described that AMPK inhibits energy-consuming pathways in 
conditions of starvation and increases energy-producing one, we performed 
Western Blot analysis in order to evaluate the phosphorylation state of AMPK in 
cells under hypoxia. As shown in figure 14D, threonine phosphorylation of 
AMPK increased in MDA-MB-231 after 7 days of hypoxia as compared to cells 
cultured under normoxia.  
All together, the obtained data confirm the lowering of energy metabolism under 
chronic hypoxia conditions and highlight another characteristic of cancer cells in 
dormant state. 
4.4 Chronic hypoxia induces different protein profile in MDA-MB-231  
In order to evaluate protein expression profile of chMDA-MB-231, we performed 
Western Blot analysis of some proteins crucial for the development of cancer. As 
shown in Figure 14B, the expression of various proteins was down-modulated in 
chMDA-MB-231, suggesting a clear difference between the protein expression 
profile of cells cultured under normoxia and hypoxia. Therefore, we analyzed the 
phosphorylation state of eIF2α, a key factor in the modulation of global protein 
synthesis (110). It has been described that different cellular stresses phosphorylate 
eIF2 on serine 51 resulting in the promotion of a pro-adaptive signaling pathway 
by the inhibition of global protein synthesis (111). As shown in Figure 14E, the 
phosphorylation of eIF2α increased in chMDA-MB-231 compared to parental cell 
line. 
4.5 Chronic hypoxia selects cancer stem cells population    
As described in the Introduction Section, hypoxic TME exerts a physiological 
pressure that selects cells with stemness properties. This sub-population promotes 
tumor invasion, metastasis and overcomes standard therapies. Furthermore, CSCs 
are able to induce tumorspheres formation (112). 
In order to investigate whether chMDA-MB-321 were characterized by stemness 
markers, we performed a flow cytometry analysis of CD24, CD44 and ESA, that 
are characteristics markers of breast cancer stem cells (112,113). We found that 
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chMDA-MB-231 cells were CD24- (data not shown) and displayed an up-
modulation of CD44 and ESA expression in comparison with the parental cell line 
(Figure 15A).  
In order to test the ability of chronic hypoxia to induce tumorspheres formation, 
the floating cells in the culture medium of chMDA-MB-231 cells (F-chMDA-
MB-231), were analyzed by Trypan Blue assay and flow cytometry F-chMDA-
MB-231 cells were still viable, CD24- (data not shown) and express higher level 
of CD44 and ESA in comparison to parental cells (Figure 15A). The cells were 
seeded at low density on coated 96 multiwell plates and cultured under hypoxic 
condition for 10 days. Images of cells were taken at days 1, 3, 5, 7 and 10 to 
visualize the formation of tumorspheres. After 3 days of hypoxia, the cells were 
able to form tumorspheres of at least 80 μm that were able to proliferate reaching 
the diameter of 150 μm after 10 days (Figure 15B). Live cell imaging of 
tumorspheres after 10 days, stained with a nuclear probe (Hoechst) and a plasma 
membrane marker (CellMask) are reported in Figure 15C.  
Furthermore, chMDA-MB-231 tumorspheres (150 μm diameter) were able to re-
differentiate into adherent cells re-acquiring epithelial morphology after 7-10 days 
of culturing in normoxic condition (Figure 15B).  
As expected, parental cell line MDA-MB-231 did not show the formation of 
tumorspheres under normoxia conditions (data not shown). 
 
 
 
 
 
 
 
 
 
Results 
 
 45  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15 Chronic hypoxia selects cancer stem cells population. (A) Cell surface expression of 
CD44 and ESA in MDA-MB-231 and chMDA-MB-231. Left. Flow cytometry pattern. Right. 
Quantitative comparison (MFI). Bar graphs represent the mean ± SE of at least four independent 
*P < 0.01 versus normoxic condition. (B) Phase-contrast microscopy images of tumorospheres 
formation starting from the viable floating cells in the culture medium of chMDA-MB-231 on day 
1, 3, 5, 7, and 10. The image of RchMDA-MB-231 (150 μm diameter) reoxygenated in fresh 
medium was analyzed too (R-). Representative images from three separate experiments are shown. 
Scale bar 50 μm. (C) Confocal live cell microscopy of spheroids after 10 days under chronic 
hypoxia stained with nuclear probe Hoechst and plasma membrane marker CellMaskDeep. 
Representative images from three separate experiments are shown. 
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4.6 Autophagy sustains MDA-MB-231 under chronic hypoxia 
It is now recognized that autophagy is not only a cellular process that removes 
damaged cellular components but also promotes cell survival during stress 
conditions of cancer cells (85). Moreover, it has been reported that autophagy 
induction may also contributes to tumor dormancy (96). 
We examined the activation of autophagic process in chMDA-MB-231 through 
the formation of autolysosomes (autophagic vesicles fused with lysosomes) using 
the fluorescent probe AO, which changes fluorescence emission from green to red 
upon accumulation into lysosomal acidic compartments. Live cell staining with 
AO revealed a significant increase of red dots in the cytosol of chMDA-MB-231 
as compared to MDA-MB-231 cultured under normoxia where AO displayed 
mainly a diffuse green pattern (Figure 16A). The induction of autophagy was 
supported by six-fold MDC uptake increase in chMDA-MB-231 cells (Figure 
16B).  
To confirm the activation of autophagy, we also examined the presence of LC3-II 
by Western Blot. As described before, during activation of the autophagic process, 
LC3-I is cleaved and conjugated with phosphatidylethanolamine to form LC3-II. 
As expected, under chronic hypoxic conditions Western Blot showed increased 
LC3-II accumulation (Figure 16C). 
It has been previously demonstrated that epithelial ovarian cancer cells enter a 
dormant state and survive through autophagy controlled in part by decreased AKT 
signaling (114,115). Western Blot analysis showed that serine phosphorylation of 
AKT was down-regulated in chMDA-MB-231 cells compared to MDA-MB-
231cells cultured under normoxia (Figure 16C). The AKT kinase has a crucial 
role in the PI3K/AKT/mTOR pathway, which phosphorylates numerous targets to 
regulate cellular functions including growth, proliferation and survival (116). 
Since the protein level of 70S6K, a downstream target of mTORC1, was 
decreased in chMDA-MB-231, we could not verify the activation of this protein.    
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Fig. 16 Analysis of autophagy in chMDA-MB-231. (A) Confocal microscopy of MDA-MB-231 
after Acridine Orange staining. Scale bar 10 µm. The image are representative of three biological 
replicates. The red dots in the cytosol of chMDA-MB-231 indicate the formation of 
autolysosomes. (B) Monodansylcadaverine incorporation assay in MDA-MB-231 and chMDA-
MB-231 cells. Bar graphs represent the mean ± SE of at least three independent replicates, each 
performed using three technical replicates.*P < 0.05. (C) Western blot of the autophagy-related 
protein LC3 and of the serine phosphorylation state of AKT in MDA-MB-231 (N) and chMDA-
MB-231 (ch). The induction of autophagy was confirmed by the appearance of LC3-II that is 
downregulated in chMDA-MB-231 cells compared to the parental cells. AKT expression was used 
as control loading. The images are representative of four independent experiments. 
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In order to verify the contribute of the autophagic process to chMDA-MB-231 
survival under chronic hypoxia, the cells were treated with chloroquine, a well-
known inhibitor of autophagy. Once established the non-toxic concentration of 
chloroquine for the cells, MDA-MB-231 and chMDA-MB-231 were treated with 
20 and 40 µM chloroquine for 72 h. The viability of chMDA-MB-231 cells, was 
more affected than that of MDA-MB-231 cells after treatment with both 
concentrations of chloroquine indicating that autophagy could contribute to the 
survival of chMDA-MB-231 under chronic hypoxia (Figure 17).           
 
Fig 17.  Cell viability after treatment of chloroquine in MDA-MB-231 and chMDA-MB-231. 
The inhibition of autophagy by treatment with chloroquine in chMDA-MB-231 results in lower 
cell viability than MDA-MB-231 cells. Bar graphs represent the mean ± SE of three independent 
experiments. *P < 0.05. 
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5. DISCUSSION 
TME, comprising a network of different components, regulates tumor initiation 
and development, contributes to metastasis appearance and has profound effects 
on the efficacy of therapies. TME is characterized by an irregular vasculature, 
which impairs blood flow in tumors and causes different regions of hypoxia. 
Some studies show that tumor cells adapt themselves to hypoxia, modifying their 
growth, metabolism and resistance to chemotherapy. Cells exposed to hypoxia as 
well as to consecutive cycle of hypoxia/reoxygenation, can enter a quiescent state 
that induces them to dormancy. Although dormant cancer cells do not directly 
contribute to tumor growth, they can be a reservoir and a source of tumorigenic 
cancer stem cells.  
The lack of established in vitro models of tumor dormancy represents one of the 
major factors that hamper the understanding of dormant cells responses and a 
hypoxia-resistant cell line might be useful for the study of cancer dormancy. 
Herein, we demonstrate that chronic hypoxia conditions, that mimics TME 
enriche MDA-MB-231 cells for a dormant cells population that is normally under-
represented in the parental cell line. We exposed different breast cancer cell lines 
to repetitive cycle of hypoxia/reoxygenation but most of them did not survive 
after 1-2 cycles. Only MDA-MB-231 cells were able to adapt to repetitive cycles 
of hypoxia/reoxygenation and survive under prolonged hypoxic condition.  
Disputed data concerning the ability of breast cancer cells to survive in hypoxic 
conditions are present in the literature. Although some researchers established  
human breast MCF7 hypoxia-resistant cell line, in our hands, these cells did not 
survive after two cycles of hypoxia/reoxygenation. These differences may be due 
to the use of different culture conditions (i.e. cellular density and medium 
composition) and type of hypoxia induction (i.e. cobalt chloride) in comparison to 
our model (117,118). It is important to note that triple negative MDA-MB-231 
cell line is one of the most aggressive among breast cancer cell lines analyzed and 
this feature might contribute to survival of the cells in adverse conditions. 
The chMDA-MB-231cell line established in this work, shows decreased 
proliferation, arrest in G0/G1 phase and low metabolic rate that are characteristic 
features of dormant state. Previous studies from Aguirre-Ghiso laboratory showed 
Discussion 
 
 50  
that proliferating human head, and neck carcinoma cell line HEp3, displayed a 
high p-ERK/p-p38 ratio that favors proliferation in vivo. Reprogramming cells 
into dormant HEp3 presented a reversion of this ratio that resulted in a prevalence 
of p-p38 over p-ERK signaling (35,37,41). Accordingly, we demonstrated that 
p38 phosphorylation was increased in MDA-MB-231 after 7 days of hypoxia, 
resulting in a lower p-ERK/p-p38 ratio that induced a prolonged phase of 
dormancy.   
When the cells adapt their metabolic activity to TME conditions, AMPK acts as a 
metabolic checkpoint by activating catabolic process and inhibiting anabolic 
metabolism. Our study shows that AMPK was activated in MDA-MB-231 starting 
from 7 days of hypoxia suggesting that AMPK activation could regulate cellular 
energy homeostasis through the autophagic recycling of intracellular components, 
as recently described (119,120). 
Some works report that hypoxia promotes autophagy as cells survival mechanism 
in the tumor mass as well as in tumor lines (96). In addition to this, many reports 
describe that oxidative stress, induced by the ROS increase and GSH depletion, 
directly correlates with autophagy activation (121-124). Accordingly, we 
measured an increase of ROS production and decrease of GSH concentration in 
chMDA-MB-231 cell line. Furthermore, we found that chMDA-MB-231 cells 
have a high level of autophagy, as analyzed by the detection of autophagolysomes 
and LC3-II expression, suggesting that autophagy may be the survival mechanism 
of dormant chMDA-MB-231 cells. As previously described, in chronic hypoxia 
inhibition of AKT activity is necessary for the activation of autophagy (125) and 
it is also crucial for the induction of dormancy and survival of cancer cells (44). In 
accordance with these data, AKT serine phosphorylation was suppressed in 
chMDA-MB-231 respect to the parental cell line in normoxia, preserving the 
energy source by decreasing energy demand. Protein synthesis is one of the most 
energy-demanding process and the initiating factor eIF2α plays an important role 
in the down regulation of protein synthesis in response to hypoxic stress (110). 
Our data, consistent with this notion, show an increase of the phosphorylation of 
eIF2α in chMDA-MB-231 compared to parental cell line, confirming the arrest of 
the protein synthesis in response to hypoxia.  
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It is known that hypoxia exposures can drive a reversible phenotype that enhances 
stem-like properties of cells to ensure survival of the tumor. Moreover, recent 
evidences reveal a correlation between cell dormancy and stemness, even if the 
mechanisms underlying these two phenomena remain discussed. The data of this 
work demonstrate that, different cycles of hypoxia/reoxygenation select a MDA-
MB-231 population that presents the characteristics stemness phenotype of CSCs 
CD24-/CD44+/ESA+ and generates tumorspheres. It is widely described that 
spheroids have a clinical and biological relevance in many tumors (126-128). It is 
well accepted that spheroids cultures more properly mimic the cell-cell or cell-
matrix interactions, metabolic gradients, cellular viability and differentiation of 
malignant cells within tumor mass than the monolayers cells culture do (129). 
We believe that this study describes a valid in vitro approach to select dormant 
cancer cells that own stemness properties using hypoxia /reoxygenation regime. 
This may represent an area with profound implications for therapeutic 
developments in oncology. 
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Metastatic Breast Cancer Cells Enter Into Dormant State
and Express Cancer Stem Cells Phenotype Under Chronic
Hypoxia
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ABSTRACT
Tumor dormancy is a poorly understood stage in cancer progression characterized by mitotic cycle arrest in G0/G1 phase and lowmetabolism.
The cells survive in a quiescent state and wait for appropriate environmental conditions to begin proliferation again giving rise to metastasis.
Despite their key role in cancer development and metastasis, the knowledge about their biology and origin is still very limited due to the
poorness of established in vitro models that faithfully recapitulated tumor dormancy. Using at least three cycles of 1% O2 hypoxia and
reoxygenation, we establish and characterize the hypoxia-resistant human breast cancer cell line chMDA-MB-231 that can stably survive
under 1% O2 condition by entering into dormant state characterized by arrest in G0/G1 phase and low metabolism. This dormant state is
reversible since once replaced in normoxia the cells recover the proliferation rate in 2weeks.We show that chronic hypoxia induces autophagy
that may be the survival mechanism of chMDA-MB-231 cells. Furthermore, the data in this work demonstrate that cycling
hypoxic/reoxygenation stress selects MDA-MB-231 population that presents the cancer stem-like phenotype characterized by
CD24/CD44þ/ESAþ expression and spheroid forming capacity. We believe that our study presents a promising approach to select dormant
breast cancer cells with stem-like phenotype using the hypoxia/reoxygenation regimen that may represent an area with profound implications
for therapeutic developments in oncology. J. Cell. Biochem. 118: 3237–3248, 2017. © 2017 Wiley Periodicals, Inc.
KEY WORDS: CHRONIC HYPOXIA; DORMANCY; AUTOPHAGY; CANCER STEM CELLS; TUMORSPHERE
Breast cancer is one of the most frequent cancers among womenworldwide and despite the introduction of new therapy a
signiﬁcant portion of patients shows diseases recurrences. Although
progress has beenmade in treating early-stage breast cancer, there is no
effective strategy topreventor treatmetastasis,which is themajor cause
of breast cancer-related mortality. Recent studies have described a
subpopulation of cancer cells within breast cancers, termed “cancer
stem cells” (CSCs) which have stem like properties and are responsible
for tumor initiation, growth,metastasis and resistance to chemotherapy
or radiation therapy. Despite their role as central players in cancer
biology, our knowledge about their biology and origin is still very
limited even if it is nowclear that the tumormicroenvironment provides
a breeding ground for CSCs selection and evolution [Dales et al., 2005;
Semenza, 2012b; Aguirre-Ghiso et al., 2013; Hensel et al., 2013].
Because of incomplete blood vessel networks and the imbalance
betweenproliferation and angiogenesis, themicroenvironment in some
parts of a solid tumor canbehypoxic andpoorly suppliedwithnutrients
[Pouyssegur et al., 2006; Denko, 2008]. The hypoxia/reoxygenation
cycles that occur frequently within tumor tissue, lead to a rapid tumor
progression so that a hypoxic microenvironment has been recognized
as a cause of malignancy or resistance to various cancer therapies
[Aguirre-Ghiso, 2007]. Investigating the biology of tumor cells in
hypoxic conditionsmight be critical for improving therapeutic efﬁcacy
and for eradication of cancer. After the discovery of hypoxia-inducible
factor-1a (HIF-1a), transcriptional regulation in response to acute
hypoxia has been quite well elucidated [Semenza, 2012a]. Otherwise,
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the effect of a chronic exposure to hypoxia and reoxygenation cycles
remains elusive [Bristow and Hill, 2008]. Although most of the tumor
cells die in chronic hypoxia, some of them, characterized by mitotic
arrest in G0/G1 phase and metabolic suppression, can survive for more
than several days in a quiescent state. This dormant state is reversible,
with tumor cells recovering the ability to self-renew once closed vessels
reopen or new vasculatures reach the hypoxic areas. Because dormant
tumor cells may be the founders of metastasis, one hypothesis is that
these cells, or at least a fraction of them, share stem cell-like
characteristics that may be responsible for their long half-lives.
In recent years, considerable progress has been made in
understanding how tumor cells circulating in the blood interact
and extravasate into secondary sites and which factors might
determine whether these cells survive, remain dormant, or become
metastases. It has been reported that phospho-ERK/phospho-p38
ratio represents the molecular switch for induction of tumor cell
dormancy. High phospho-ERK/phospho-p38 ratio promotes cells
proliferation and metastasis formation. Conversely, in restrictive
microenvironments, low phospho-ERK/phospho-p38 ratio induces
both G0/G1 arrest and survival signals, which will in turn lead to a
prolonged phase of dormancy [Adam et al., 2009]. In addition,
activation of p38 signaling in these cells promotes pro-survival
mechanism via the up regulation of endoplasmic reticulum stress
that results in unfolded protein response. Furthermore, it has been
demonstrated that suppression of AKT activity, a keymolecule in cell
proliferation and metabolism, is necessary for induction of
dormancy and survival of the cancer cells [Endo et al., 2014].
Recent reports suggest that microenviromental stress activates
autophagy, the bulk degradation of cellular material that allows cells
to recycle both nutrients and energy and functions as a ﬁtness
mechanism [Jain et al., 2013].
An understanding of the regulatory machinery of tumor
dormancy is essential for identifying early cancer biomarkers and
could provide a rationale for the development of novel agents to
target dormant tumor cells population. The lack of established in
vitro models of tumor dormancy represents the major factor that
hampers the understanding of dormant cells response. Indeed, the
majority of in vitro hypoxia studies have been carried out exposing
cell lines to acute hypoxia (3–24 h) whereas only few reports of
chronic hypoxia have been published.
In the current study, we ﬁnd that human breast cancer cell line
MDA-MB-231 can stably survive by entering into dormant state
after at least three cycles of hypoxia (1% O2) and reoxygenation and
that autophagy sustains viability of cells in hypoxic conditions. In
this contest, chronic hypoxia acts as a physiological selective
pressure for the expansion of CSCs that acquire sphere-forming
capacity and exhibit an outstanding CD24/CD44þ/ESAþ stem-like
phenotype.
MATERIALS AND METHODS
CELL LINES AND CELL CULTURE
Human breast cancer cell lines MDA-MB-231, MDA-MB-468, T47D,
and MCF-7 were purchased from American Type Culture Collection.
All the cell lines were cultured in DMEM (LifeTechnologies)
supplemented with 10% FBS, 100UI/ml penicillin, 100mg/ml
streptomycin, and 40mg/ml gentamycin (Life Technologies) in a
5% CO2 atmosphere at 37°C. Hypoxic culture was achieved by
incubating cells with 1% O2 and 5% CO2 in a Multigas Incubator
(RUSKINN C300, RUSKINN Technology Ltd) in DMEM without
sodium pyruvate and supplemented with 25mM Hepes, 10% FBS,
100UI/ml penicillin, 100mg/ml streptomycin, and 40mg/ml
gentamycin.
MORPHOLOGICAL ANALYSES OF DORMANT CELLS AND
TUMORSPHERES
Approximately 6 104 MDA-MB-231 and chMDA-MB-231 cells
were seeded on a 4-chamber mslide, with 13mm glass bottom (Ibidi
GmbH). After 24 h, cells were incubated for 5min with a staining
solution made of CellMaskDeep Red (LifeTechnologies) 1:1000 in
complete cell media. Before the acquisition, the medium was
replaced with a special medium without phenol red (DMEM/F12
NoPhenolRED, LifeTechnologies) to avoid any interference with the
ﬂuorescence signal.
The tumospheres deriving from 60 wells of a coated 96 well-plate
were gently collected by a p1000 tip with a cut extremity and seeded
on a 4-chamber mslide. After 24h, cells were incubated for 60min
with a staining solutionmadeofCellMaskDeepRed (LifeTechnologies)
1:1000 and Hoescht 1:1000 (LifeTechnologies) in DMEM/F12
NoPhenolRED. Cell images were captured using a confocal laser-
scanning ﬂuorescence microscope Leica SP5 (Leica Microsystem) at
63magniﬁcationandprocessedusingAdobePhotoshopand ImageJ
softwares (Rasband, W.S., ImageJ, U. S. National Institute of Health,
Bethesda, Maryland, http://rsb.info.nih.gov/ij/, 1997–2008).
CELLS VIABILITY
The viability of MDA-MB-231 and chMDA-MB-231 cells were
evaluated with a 0.1% Trypan Blue exclusion test using a Countess
Automated Cell Counter (LifeTechnologies).
IMMUNOPHENOTYPE
Cells were harvested, washed in phosphate buffer saline (PBS) and
stained with anti-human CD326/ESA-FITC, CD24-FITC (Miltenyi
Biotec), CD44-PE (BD Pharmingen). After incubation at room
temperature for 15min, cells were washed in PBS, acquired on a
FACScan cytometer (Becton Dickinson) and analyzed by FlowJo
9.3.3 software (Tree Star). Data were expressed as the difference of
Median Fluorescence Intensity (MFI) between stained and unstained
cells.
CELL CYCLE
Cells were incubated with 10mM Vybrant DyeCycle orange stain
(LifeTechnologies) for 15min and with 1mM Sytox Blue dead Cell
stain (LifeTechnologies) for additionally 15min to exclude dead cells
from cytometric analysis.
CELL PROLIFERATION
Cells were labeled with the amine-reactive dye 5,6-carboxyﬂuor-
escein diacetate, succinimidyl ester (CFSE), as described previously
[Rigo and Vinante, 2016]. This dye is incorporated into cells and
divided equally into daughter cells during proliferation. Thus, cells
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proliferation can be determined by measuring the MFI by ﬂow
cytometry on a FACS can ﬂow cytometer. Brieﬂy, they were
resuspended at a ﬁnal concentration of 107 cells/ml in PBS-5% FBS
and incubated with 5mM CFSE for 5min at room temperature. The
reaction was stopped by washing twice with PBS-5% FBS. Cells were
replated at 106 cells/ml in complete medium in normoxic and
hypoxic conditions. An aliquot of cells was harvested every 24 h for
3 days, added with TO-PRO-3 (LifeTechnologies) and subjected to
ﬂow cytometry analysis.
MEASUREMENT OF GLUCOSE, PYRUVATE, AND LACTATE
CONCENTRATION
After 3–5 days of culture under normoxic or hypoxic conditions the
medium of MDA-MB-231 and chMDA-MB-231 cells were harvested
and cells were counted. The concentration of glucose and lactate
in the media was measured by using the glucose assay kit
(CaymanChemical) and the lactate assay kit (Megazyme
International), respectively, according to the manufacturer’s in-
structions. To measure the amount of pyruvate produced, 5–50ml of
medium were added to 370mM Tris–HCl pH 8, containing 350mM
NADH and 3mg of LDH (Sigma), to aﬁnal volume of 300ml. The total
change of the absorbance at 340 nm was measured and using the
molar extinction coefﬁcient of NADH at 340 nm (6,220M/cm), the
moles of NADH oxidized, that are equal to the moles of pyruvate
produced, were calculated.
GLUTATHIONE CONTENT QUANTIFICATION
The intracellular GSH concentration was measured by endpoint
spectrophotometric titration on a Jasco V/550 spectrophotometer
(JASCO)using the5,50-dithiobis(2-nitrobenzoic acid) (DTNB,Ellman’s
reagent) [Butturini et al., 2013]. Brieﬂy, MDA-MB-231 and chMDA-
MB-231 cells were lysed by freezing and thawing in 100mM sodium
phosphate buffer, pH 7.5, containing 5mM EDTA, (KPE buffer), and
after centrifugation at 16,000 rpm for 10min, total protein concen-
tration was determined by using Bradford method [Bradford, 1976].
The supernatants were deproteinizedwith 5% trichloroacetic acid. For
[GSH] measurement, acidiﬁed clear supernatants were neutralized
and buffered at pH 7.4with 200mMK2HPO4, pH 7.5. The reactionwas
then started by the addition of 60mM DTNB and the increase in
absorbance at 412nmwas measured until no variation in absorbance
was evident. The amount of total GSHwas determined by comparison
with GSH standard curve.
DETECTION OF INTRACELLULAR REACTIVE OXYGEN SPECIES
CM-H2DCFDA staining. MDA-MB-231 and chMDA-MB-231 cells
were resuspended in HBSS (LifeTechnologies) at 3 105 cells/ml
and loaded with 2.5mM of the cell-permeant probe 5-(and-6)-
chloromethyl-2’7’-dichlorodihydroﬂuorescein diacetate acetyl es-
ter (CM-H2DCFDA; Molecular Probes) for 1 h at 37°C, as previously
described [Butturini et al., 2011]. ROS generation was evaluated in
ﬂow cytometry (Becton Dickinson) by measuring the green
ﬂuorescence signal (Fl-1) of CM-H2DCFDA that occurs after
removal of the acetate groups by intracellular esterases and
oxidation by free radicals. Data were analyzed by FlowJo 9.3.3
software.
Mitosox staining. Approximately 6 104 MDA-MB-231 and
chMDA-MB-231 cells were seeded on a 4-chamber mslide, with
13mm glass bottom (Ibidi GmbH). After 24 h, cells were incubated
for 30min with a staining solution made of Mitosox 1:1000
(LifeTechnologies), Mitotracker greenFM 1:5000 (LifeTechnologies),
and Hoescht 1:1000 (LifeTechnologies) in medium without FBS.
Before the acquisition, the medium was replaced with a medium
without phenol red (DMEM/F12 NoPhenolRED, LifeTechnologies) to
avoid any interference with theﬂuorescence signal. Cell images were
captured using a confocal laser-scanning ﬂuorescence microscope
Leica SP5 at 63 magniﬁcation and processed using Adobe
Photoshop and ImageJ softwares (Rasband, W.S., ImageJ, U. S.
National Institute of Health, Bethesda, Maryland, http://rsb.info.nih.
gov/ij/, 1997–2008).
WESTERN BLOT
Cells were homogenized at 4°C in 20mM Hepes, pH 7.4, containing
420mM NaCl, 1mM EDTA, 1mM EGTA, 1% Nonidet-P40 (NP-40),
20% glycerol, protease cocktail inhibitors (GE Healthcare). Protein
concentration was measured by Bradford reagent (GE Healthcare),
using bovine serum albumin as standard. Protein extracts
(50mg/lane) were resolved by SDS–PAGE electrophoresis and
transferred to PVDF membrane (Immobilon P, Millipore). Immuno-
blotting assays were carried out by standard procedures
using anti-LC3, anti-phospho(Thr180/Tyr182)-p38, anti-p38,
anti-phosphoSer-AKT, anti-AKT, anti-phosphoThr-AMPKa, anti-
AMPKa and anti-P70S6 kinase antibodies (Cell Signaling Technol-
ogy), anti-STAT1, anti-STAT3, anti-p53, anti-phospho(Thr202/
Tyr204)-ERK, and anti-ERK antibodies (Santa Cruz Biotechnology),
anti-HIF1a antibody (BD biosciences), anti-actin antibody
(Millipore), anti-HIF2a antibody (Novus Biologicals). After washing,
membranes were developed using anti-rabbit or anti-mouse IgG
peroxidase-conjugated antibody (Cell Signaling Technology) and
chemiluminescent detection system (Immun-Star WesternC Kit,
Bio-Rad). Blotted proteins were detected and quantiﬁed using the
ChemiDoc XRS Imaging System (Bio-Rad).
REAL-TIME PCR
Cellular RNA was extracted by PureLink Total RNA kit (Ambion)
according to the manufacturer’s instructions. Total RNA was
quantiﬁed at 260/280 nm, and the integrity of the samples was
checked by 1% agarose gel electrophoresis. Aliquots corresponding
to 1mg of total RNA were reverse transcribed by using the
SuperScript Vilo cDNA synthesis kit (LifeTechnologies) following
the manufacturer’s protocol. Aliquots of the cDNAs (corresponding
to 50 ng of the original RNA) were subjected to real-time PCR with
the QuantiTect SYBR Green PCR Kit (Qiagen) following the
manufacturer’s instructions. Bioinformatically validated primer
sets for real-time PCRs were purchased by Qiagen (QuantiTect
Primer Assays: Hs_RRN18S_1_SG for 18S, Hs_PGK_1_SG for PGK,
Hs_SLC2A1_1_SG for GLUT1, and Hs_GADPH_2_SG for GAPDH).
The PCR was performed with an initial pre-incubation step for
15min at 95°C, followed by 45 cycles of 94°C for 15 s, annealing at
55°C for 30 s, and extension at 72°C for 30 s. The speciﬁcity of the
ampliﬁed products was monitored performing melting curves at the
end of each ampliﬁcation reaction. All amplicons generated a single
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peak, thus reﬂecting the speciﬁcity of the primers. Real-time PCR
was performed using the Rotor-Gene 6000 (Corbett) and data
analysis was conducted using the Rotor-Gene Software. Data were
normalized to 18S and sample expression levels are shown as
percentages of the internal control gene.
DETECTION OF AUTOPHAGIC MARKERS
Acridine orange staining. Approximately 6 104 MDA-MB-231
and chMDA-MB-231 cells were seeded on a 4-chamber mslide, with
13mm glass bottom (Ibidi GmbH). After 24 h cells were rinsed in PBS
and stained with acridine orange (AO) (1:1500 in PBS). Cell images
were captured immediately by using a confocal laser-scanning
ﬂuorescence microscope Leica SP5 (Leica Microsystem) at 63
magniﬁcation and processed using Adobe Photoshop and ImageJ
softwares (Rasband, W.S., ImageJ, U. S. National Institute of Health,
Bethesda, Maryland, http://rsb.info.nih.gov/ij/, 1997–2008).
Monodansylcadaverine staining and autolysosome formation
assay. MDA-MB-231 and chMDA-MB-231 cells were incubated
with the ﬂuorescent probe monodansylcadaverine (MDC; Sigma) a
selective marker for acidic vesicular organelles, such as autophagic
vacuoles. Brieﬂy, cells were seeded in 96-well plates (3 104 cells/
well) and after 24 stained with acridine orange were incubated in
culture medium containing 50mM MDC at 37°C for 15min. Cells
were then washed with Hanks buffer (20mM Hepes pH 7.2, 10mM
glucose, 118mM NaCl, 4.6mM KCl, and 1mM CaCl2) and
ﬂuorescence was measured using a multimode plate reader
(Ex340 nm and Em535 nm) (GENios Pro, Tecan). The values were
normalized for cell proliferation by Crystal Violet assay.
LC3-II. The presence of lipidated LC3-II isoform was analyzed by
Western Blot as described above using mouse anti-LC3I/II antibody
that detects endogenous levels of LC3B isoforms I and II.
STATISTICAL ANALYSIS
Data are reported as means SE of four independent experiments
(n¼ 4); statistical analyses were performed using Student’s t test.
RESULTS
SURVIVAL OF MDA-MB-231 CELL LINE UNDER CHRONIC HYPOXIA
In order to establish an in vitro model of breast cancer hypoxia-
resistant cells, we cultured MDA-MB-231, MDA-MB-468, T47D, and
MCF-7 cell lines in 1% O2 atmosphere for 1–3 days and exposed the
surviving cells to reoxygenation for 1–3 weeks depending on the
rescue of cells and their proliferation rate. Only MDA-MB-231 cells
were able to recover their proliferation rate and grow until the
conﬂuence. The cells were then exposed to repetitive cycles of
hypoxia/reoxygenation. We set up the hypoxia/reoxygenation
conditions with regard to number of cycles and exposure time.
The optimized procedure included exposure of the MDA-MB-231
breast cancer cells up to 7 days to hypoxia and reoxygenation of the
surviving cells for 7–10 days depending on the viability of surviving
cells. After reoxygenation and growing, we exposed the cell line
again to a second round of hypoxia, and found an increase in
viability. After three rounds of hypoxia and oxygenation, the
cells, designed as chronic hypoxia resistant MDA-MB-231
(chMDA-MB-231), were able to stably grow in hypoxia even if
with a decreased proliferation rate. chMDA-MB-231 cells were
cultured under hypoxia for 3 months.
Cell cycle analysis revealed that the new established
hypoxia-resistant chMDA-MB-231 cells were accumulated in
G0/G1 phase and the percent in G2/M phase was drastically
reduced (Fig. 1A).
Analysis of CFSE dilution showed a lesser decrease of ﬂuores-
cence in chMDA-MB-231 respect to MDA-MB-231 cells after 24, 48,
and 72 h of culture under hypoxia or normoxia, respectively
(Fig. 1B). These data indicate that chMDA-MB-231 cells have a lower
proliferation capacity than parental cells.
The arrest in G0/G1 phase and the low proliferation rate were
reversible since, once replaced into freshmedium and re-oxygenized
the cells, designed as reverted chronic hypoxia resistant
MDA-MB-231 (RchMDA-MB-231), showed a recovery of the
proliferation rate in 2 weeks (Fig. 1A and B).
Furthermore, chMDA-MB-231 cells displayed apparent morpho-
logical differences as showed by live confocal microscopy experi-
ments were the plasmamembrane was stained with CellMask dye. As
compared to the parental cells, dormant chMDA-MB-231 cells show
a longer and tapered shape and a higher cellular volume (Fig. 1C).
Differently from the parental cells, chMDA-MB-231 cells viability
was less affected by doxorubicin, one of the most effective agents in
the treatment of breast cancer patients (Fig. 1D).
These results indicated that chMDA-MB-231 cells reversibly
entered an inactive status, dormancy, under prolonged hypoxic
condition.
In order to investigate the kinetic of dormant status induction,
MDA-MB-231 cells were cultured in hypoxic condition until 7 days.
As shown in Figure 2, phospho-p38 increased after 3 days of culture
in hypoxia reaching a high level of phosphorylation after 7 days
whereas phosphorylation of ERK was almost the same at all the time
points examined. The densitometric analysis shows that the ratio of
phospho-ERK/phospho-p38 in MDA-MB-231 cells cultured in
hypoxia was reduced as compared to MDA-MB-231 cells in
normoxia starting from 7 days.
EVALUATION OF REDOX STATE UNDER CHRONIC HYPOXIA
The redox environment in chronic hypoxic condition was evaluated
measuring ROS production and GSH concentration.
chMDA-MB-231 cell line loaded with CM-H2DCFDA, a speciﬁc
cell-permeant ROS indicator, exhibited a clear ﬂuorescence increase
as respect to parental cell line (MFIchMDA-MB-231¼ 1344 541 vs.
MFIMDA-MB-231¼ 331 71, Fig. 3A). These data are consistent with
an enhancement of intracellular ROS. Moreover, the intracellular
GSH concentration, analyzed by DTNB staining, was lower in
chMDA-MB-231 cell line compared to parental cells (10.60 2.00
nmoles/mg proteins versus 20,70 1,50 nmoles/mg proteins,
Fig. 3B).
At the same time, confocal live microscopy analysis revealed a
marked increase of mitochondrial ROS production in dormant
chMDA-MB-231 cells as indicated by the appearance of a red signal,
originated by the oxidation of the MitoSOX red reagent, which co-
localizes with that of the mitochondrial marker (MitoTracker)
(Fig. 3C).
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EVALUATION OF ENERGY METABOLISM UNDER CHRONIC HYPOXIA
We further assessed the status of energy metabolism of the cancer
cells in the dormant state.We analyzed glucose consumption, as well
as pyruvate and lactate production in the supernatants of MDA-MB-
231 and chMDA-MB-231 cells. The results obtained indicated that
the metabolism of dormant cells was strongly attenuated compared
to MDA-MB-231 cells, as shown by the reduced levels of glucose
consumed and pyruvate/lactate produced (Fig. 4A). Moreover, while
under normoxic conditions the amount of lactate produced is
3.3-fold lower than that of pyruvate, under hypoxic conditions the
amounts of pyruvate and lactate are similar. These data suggest that
under normoxic conditions the aerobic catabolism of pyruvate
prevails while under hypoxic conditions the anaerobic lactic
fermentation occurs at signiﬁcant extents.
Next, we examined the expression of HIF-1a, a master regulator
of energy metabolism network under hypoxic condition. As a
transcriptional activator, HIF-1a can induce the expression of target
genes that promote angiogenesis, glycolysis, cellular proliferation,
Fig. 1. MDA-MB-231 cell line can survive under chronic hypoxia entering into dormant state (a) Right. Flow cytometry analysis of cell cycle in MDA-MD-231 cells and in
chMDA-MB-231. The cells were stained with 10mM Vybrant DyeCycle orange and with 1mM Sytox Blue (to exclude died cells from analysis). The cell cycle of chMDA-MB-231
reoxygenated in fresh medium (RchMDA-MB-231) was analyzed too. Left. Statistical analysis of the cell cycle phases. P< 0.01 (b) Right. Overlay histogram of the daily CFSE
ﬂuorescence intensity in the TO-PRO-3neg population. In MDA-MB-231 cells, CFSE is diluted among the daughter cells and ﬂuorescence intensity decreases day by day. In
chMDA-MB-231 cells, a lesser dilution of CFSE indicates decreased cell division. In RchMDA-MB-231 cells, the pattern of CFSE dilution is similar to that of MDA-MB-231 cells.
Left. Plot of the daily percentage of CFSE ﬂuorescence intensity as respect to time 0 in each condition (MFI SE, P< 0.01). (c) Confocal microscopy of MDA-MB-231 and
chMDA-MB-231 after CellMaskDeep staining. Scale bar 10mm. (d) Cell viability of MDA-MB-231 and chMDA-MB-231 cells after 24 h treatment with doxorubicin. ChMDA-
MB-231 cells show a higher chemoresistance than the parental cell line (EC50¼ 0.25mg/ml 0.05, MDA-MB-231; EC50¼ 2.00mg/ml 0.15, chMDA-MB-231).
Representative results or means SE of at least four experiments are depicted.
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and metastasis. In line with previous study [Wang et al., 2014a],
MDA-MB-231 cells expressed HIF-1a under normal oxygen
condition while chMDA-MB-231 cells present a lower level of
HIF-1a protein (Fig. 4B). As expected the expression of GLUT1,
GAPDH, and PGK genes decreased in chMDA-MB-231 (Fig. 4C).
It has been reported that a condition of energy deprivation
induces phosphorylation of AMPK that inhibits energy-consuming
pathway while increases energy-producing one. Western blot
analysis demonstrated that threonine phosphorylation level of
AMPK increased in MDA-MB-231 after 7 days under hypoxic
condition (Fig. 4D).
These results conﬁrm the lowering of energy metabolism and
point out another characteristic of cancer cells in the dormant state.
CHRONIC HYPOXIA INDUCES DIFFERENT PROTEIN PROFILE IN
MDA-MB-231
Western blot analysis revealed that the expression of various
proteins was down-modulated in chMDA-MB-231 suggesting a
different protein expression pathway between the cells cultured
under normoxia or chronic hypoxia (Fig. 4B). Therefore, we analyzed
the phosphorylation state of eIF2a, a key factor in the modulation of
global protein synthesis [Koumenis et al., 2002]. Interestingly, the
phosphorylation of eIF2a increased in chMDA-MB-231 compared to
parental cells (Fig. 4E).
AUTOPHAGY SUSTAINS MDA-MB-231 SURVIVAL UNDER CHRONIC
HYPOXIA
Autophagy is a cellular process that removes damaged or unwanted
cellular components and recycles them to build new constituents and
promotes cell survival as well as cell death. It is now recognized that
induction of autophagy in tumor cells may also contribute to tumor
dormancy [Degenhardt et al., 2006]. Autophagy induction was
examined through the formation of autolysosomes (autophagic
vesicles joined with lysosomes) using the ﬂuorescent probe AO,
which changes its ﬂuorescence emission from green to red upon
accumulation into lysosomal acidic compartments. Autophagy
induction was conﬁrmed through the detection of autolysosomes
by AO staining. Live cell staining with AO revealed a signiﬁcant
increase of red dots in the cytosol of chMDA-MB-231 cells as
compared to MDA-MB-231 cells cultured under normoxic condition
where AO displayed mainly a diffuse green pattern (Fig. 5A). The
induction of autophagy was supported by sixfold MDC uptake
increase in chMDA-MB-231 cells (Fig. 5B). To conﬁrm the activation
of autophagy, we also examined the presence of LC3-II by Western
Blot. During the activation of autophagy, LC3-I is cleaved,
conjugated with phosphatidylethanolamine (LC3-II) and associated
with newly formed autolysosomes [Kim et al., 2007, Noda et al.,
2009]. Since the lipidated form migrates slightly fast on the gel, this
can be a good marker for the activation of autophagy. As expected,
under chronic hypoxic conditions western blot showed increased
LC3-II accumulation (Fig. 5C).
It has been previously demonstrated that epithelial ovarian cancer
cells enter a dormant state and survive through autophagy
controlled in part by decreased AKT signaling [Correa et al., 2012,
2014]. Western blot analysis showed that serine phosphorylation of
AKT was down-regulated in chMDA-MB-231 cells compared to
MDA-MB-231 cells cultured under normoxic condition (Fig. 5C). The
AKT kinase is a pivotal node in the PI3K/AKT/mTOR pathway, which
phosphorylate numerous downstream targets to regulate cellular
functions including growth, proliferation and survival [Manning
and Cantley, 2007]. Unfortunately, we could not check the
phosphorylation state of 70S6K, a downstream target of mTORC1,
because the protein level of 70S6K decreased in chMDA-MB-231
cells compared to MDA-MB-231 cells cultured under normoxic
condition (Fig. 4B).
CHRONIC HYPOXIA SELECTS CANCER STEMCELLS POPULATIONAND
INDUCES TUMORSPHERES FORMATION IN MDA-MB-231
In the last years, literature reports that hypoxia exerts a physiologi-
cal pressure that promotes tumor invasion andmetastasis and selects
cells with stemness properties. This small subpopulation is
characterized by self-renewal, anoikis, and ability to form
tumorsphere.
Using theﬂow cytometry analysis,we found that chMDA-MB-231
cells were CD24 (data not shown) and displayed an up-modulation
of CD44 and ESA expression in comparisonwith the parental cell line
Fig. 2. Effect of chronic hypoxia on phosphorylation of ERK and p38 inMDA-
MB-231. Western blot analysis shows that chronic hypoxia time-dependently
triggers Thr/Tyr phosphorylation of p38 (a) whereas does not modify ERK
phosphorylation state (b) in MDA-MB-231 cells cultured under 1% O2 for the
indicated time. (c) The densitometric analysis of eachwestern blot was analyzed
by QuantityOne software. The bars represent the ratio between phosphorylation
of ERK, normalized on total ERK protein, and phosphorylation of p38,
normalized on total p38 protein. MDA-MB-231 cells cultured under normoxic
condition were used as control (N). The images are representative of four
independent experiments.
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(Fig. 6A). These are characteristic markers of breast cancer stem cells
[Wang et al., 2014b; An et al., 2015; Chen et al., 2015].
In order to test the ability of chronic hypoxia to induce
tumorsphere formation, the ﬂoating cells in the culture medium of
chMDA-MB-231 cells (F-chMDA-MB-231), were analyzed by
Trypan Blue assay. These non-adherent cells were still viable,
CD24 (data not shown) and express higher level of CD44 and ESA
in comparison to parental cells (Fig. 6A). These cells were seeded at
low density on coated 96 multiwell plates and cultured under
hypoxic condition. Images of cells from each well were taken at
days 1, 3, 5, 7, and 10 to visualize the formation of tumorspheres.
After 3 days, the cells were able to form compact and asymmetrical
tumorspheres of at least 80mm that was able to proliferate
reaching the diameter of 150mm after 10 days (Fig. 6B). Live cell
imaging of tumorspheres after 10 days, stained with a nuclear
probe (Hoechst), and a plasma membrane marker (CellMask) are
reported in Figure 6C.
Furthermore, chMDA-MB-231 tumorspheres (150mm diameter)
were able to re-differentiate into adherent cells re-acquiring
epithelial morphology after 7–10 days of culturing in normoxic
condition (Fig. 6B).
As expected, parental cell line MDA-MB-231 did not show any
tumorsphere-forming ability under normoxic condition (data not
shown).
DISCUSSION
It is known that both hypoxia and consecutive hypoxia/reoxygena-
tion can exert a variety of effects on tumor cells biology, including a
prolonged quiescent state that induce cells to enter dormancy. Some
Fig. 3. Evaluation of redox state under chronic hypoxia. (a) Flow cytometry analysis of ROS production inMDA-MB-231 and chMDA-MB-231 cells loaded with CM-H2DCFDA.
The ﬂuorescence increase in chMDA-MB-231 cells indicates a higher ROS production as respect to parental cells. (b) Spectrophotometric analysis of intracellular GSH
concentration in MDA-MB-231 and in chMDA-MD-231. The decrease of absorbance at 420 nm in chMDA-MB-231 cells indicates a lower GSH concentration as respect to
parental cells. Bar graphs represent the mean SE. P< 0.01. (c) Confocal live microscopy of MDA-MB-231 and chMDA-MB-231 after Mitosox, Mitotracker greenFM, and
Hoescht staining. Merge and single channel images come from a single zplane. Scale bar 10mm. The appearance of red signal in chMDA-MB-231 reveals an increase of
mitochondrial ROS production. Representative results of at least four experiments are depicted.
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studies have shown that hypoxia, can drive a reversible phenotype
that enhances stem-like properties of cells to ensure survival of the
tumor. Although dormant cancer cells do not directly contribute to
tumor growth, they can be a reservoir and a source of tumorigenic
cells and chemoresistance. One factor hampering improved
understanding of the response of dormant cells is the lack of
established in vitromodels and a hypoxia-resistant cell linemight be
useful for the study of cancer dormancy. The results presented here
demonstrate that chronic hypoxic condition, that mimics tumor
microenvironment, enriches MDA-MB-231 cells for a dormant
tumor cell population that is normally under-represented in the
parental tumor cell line. We exposed diverse breast cancer cell lines
to repetitive cycles of hypoxia/reoxygenation and most of them did
not proliferate and survive after 1–2 cycles. Only MDA-MB-231 cell
line was able to adapt and survive under prolonged hypoxic
condition. Controversial data concerning the ability of breast cancer
cell lines to resist to prolonged hypoxia are present in the literature.
Although some researchers establishedMCF7 hypoxia-resistant cells
[Scherbakov et al., 2009], in our hands, only MDA-MB-231 cells
survive under the chronic hypoxia and reoxygenation cycles
described. These differences may be due to the use of different
culture conditions, such as different cellular density at the moment
Fig. 4. Effect of chronic hypoxia on energy metabolism and protein expression in MDA-MB-231. (a) Analysis of MDA-MB-231 and chMDA-MB-231 cells metabolism. The
media were analyzed to deﬁne the amount of glucose consumed (&), pyruvate produced ( ), and lactate produced ( ). Bar graphs represent the meansf glucose consumed SE
of three independent experiments. P< 0.01 versus normoxic condition. (b)Western blot analysis of various proteins expression in chMDA-MB-231 (ch) compared toMDA-MB-
231 (N). Actin is used as control loading. The images are representative of four independent experiments. (c) Histograms of the analysis of GLUT1, GAPDH, and PGK gene
expression in MDA-MB-231 in normoxic and hypoxic conditions by RT-PCR. (d) Western blot analysis shows that chronic hypoxia up-regulated Thr phosphorylation of AMPK
without affecting the total amount of AMPK inMDA-MB-231. MDA-MB-231 cells cultured under normoxic condition were used as control (N). (e) Western blot analysis shows
that chronic hypoxia up-regulated Ser phosphorylation of eIF2a without affecting the total amount of eIF2 in chMDA-MB-231. MDA-MB-231 cells cultured under normoxic
condition were used as control (N). The images are representative of four independent experiments.
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of seeding, different medium composition, and different type of
hypoxia induction (i.e., cobalt chloride).
The chMDA-MB-231 cells established in this work are
characterized by a decreased proliferation, arrest in G0/G1 phase
and low metabolic rate. Previous studies from Aguirre-Ghiso
laboratory discovered that HEp3, human head and neck carcinoma
cell line, displays a high phospho-ERK to phospho-p38 signaling
ratio that favors proliferation in vivo [Aguirre-Ghiso et al., 2001,
2003, 2004]. The reprogramming of cells into dormancy (D-HEp3
cells) results in a reversion of this ratio with p38 signaling that
predominates over ERK [Aguirre-Ghiso et al., 1999, 2002; Liu
et al., 2002]. Accordingly, we demonstrated that p38 phosphor-
ylation was elevated in chMDA-MB-231 cells, resulting in a
phospho-ERK/phospho-p38 ratio that favored p38 and induced a
prolonged phase of dormancy.
Under conditions where metabolic activity is low, AMPK acts as a
metabolic checkpoint by activating catabolic processes and inhibit-
ing anabolic metabolism. Our study shows that AMPK was activated
in MDA-MB-231 starting from 7 days of hypoxia suggesting that
AMPK activation could regulate cellular energy homeostasis
through the autophagic recycling of intracellular components, as
recently described [Meley et al., 2006; Matsui et al., 2007].
Some reports describe that hypoxia promotes autophagy as a
cells survival mechanism in the tumor core as well as in tumor cell
line [Degenhardt et al., 2006]. On the other hand, lot of literatures
describe that oxidative stress induced by the ROS increase and
GSH depletion maybe directly correlated with autophagy activa-
tion [Scherz-Shouval et al., 2007; Gao et al., 2008; Li et al., 2012;
Poillet-Perez et al., 2015]. Interestingly, we found that chMDA-
MB-231 cells have a high level of autophagy, as measured by the
Fig. 5. Analysis of autophagy in chMDA-MB-231. (a) Confocal microscopy of MDA-MB-231 and chMDAMB-231 after Acridine Orange staining. Scale bar 10mm.
The images are representative of three biological replicates. The red dots in the cytosol of chMDA-MB-231 indicate the formation of autolysosomes. (b) MDC
incorporation assay in MDA-MB-231 and chMDA-MB-231 cells. Bar graphs represent the mean  SE of three independent biological replicates, each performed
using three technical replicates. P< 0.05. (c) Western blot of the autophagy-related protein LC3 and of the serine phosphorylation state of AKT in MDA-MB-231 (N)
and chMDA-MB-231 (ch). The induction of autophagy was conﬁrmed by the apparance of LC3-II. The serine phosphorylation of AKT was down-regulated in chMDA-
MB-231 cells compared to the parental cells. AKT expression was used as control loading. The images are representative of four independent experiments.
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Fig. 6. Chronic hypoxia selects cancer stem cells population. (a) Cell surface expression of CD44 and ESA inMDA-MB-231 and chMDA-MB-231. Left. Flow cytometry pattern.
Right. Quantitative comparison (MFI). Bar graphs represent the mean SE of at least four independent P< 0.01 versus normoxic condition. (b) Phase-contrast microscopy
images of tumorospheres formation starting from the viable ﬂoating cells in the culture medium of chMDA-MB-231 on day 1, 3, 5, 7, and 10. The image of F-chMDA-MB-231
(150mm diameter) reoxygenated in fresh medium was analyzed too. Representative images from three separate experiments are shown. Scale bar 50mm. (c) Confocal live cell
microscopy of spheroids after 10 days under chronic hypoxia stained with nuclear probe Hoechst and plasma membrane marker CellMaskDeep. Representative images from three
separate experiments are shown.
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detection of autophagolysome and LC3-II expression, suggesting
that autophagy may be the survival mechanism of dormant
chMDA-MB-231 cells. As previously described, in chronic hypoxia
inhibition of AKT activity is necessary for induction of dormancy
and survival of cancer cells [Endo et al., 2014]. In accordance with
these data, AKT serine phosphorylation was suppressed in chMDA-
MB-231 preserving the energy source by decreasing energy
demand. Protein synthesis is one of the most energy-demanding
metabolic processes and it has been reported that the eukaryotic
initiation factor eIF2a plays a critical role in the down-regulation
of protein synthesis in response to hypoxic stress [Koumenis et al.,
2002]. MDA-MB-231 cells are characterized by constitutively
phosphorylated eiF2a due to their increased activation of
epithelial to mesenchymal transition associated with cells migra-
tion and metastasis ability [Feng et al., 2014]. Our data, consistent
with these notions, show further increase in phosphorylation state
of eIF2a in chMDA-MB-231 compared to parental cell line that
could be correlated to the selective translation repression of
proteins.
Furthermore, the data in this work demonstrate that cycling
hypoxic/reoxygenation stress selected MDA-MB-231 population
that presents the characteristic phenotype of CSCs,
CD24/CD44þ/ESAþ and is able to generate tumorspheres. The
biological signiﬁcance and clinical relevance of multicellular
spheroids has been documented in many different tumor types
[Barbone et al., 2008; Valcarcel et al., 2008; Sodek et al., 2009;
Lawrenson et al., 2011; Wenzel et al., 2014] It is well accepted that
spheroids more closely mimic the cell–cell, cell-matrix interactions,
metabolic gradients, cellular viability, and differentiation of
malignant cells within a solid tumor than do conventional
monolayer cultures [Kunz-Schughart et al., 2000]. We believe that
our study presents a promising approach to isolate dormant cells and
stem-like breast CSCs using the hypoxia/reoxygenation regimen
that may represent an area with profound implications for
therapeutic developments in oncology.
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